504-07-4 | 5,6-Dihydrouracil

Packsize	Purity	Availability	Price	Discounted Price
1g	98%	in stock	$16.00	$11.00
5g	98%	in stock	$25.00	$17.00
10g	98%	in stock	$43.00	$30.00
100g	98%	in stock	$293.00	$205.00

Description

• Catalog Number: AG25357
• Chemical Name: 5,6-Dihydrouracil
• CAS Number: 504-07-4
• Molecular Formula: C4H6N2O2
• Molecular Weight: 114.1026
• MDL Number: MFCD00006029
• SMILES: O=C1CCNC(=O)N1
• NSC Number: 11867

Computed Properties

• Complexity: 132
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 8
• Hydrogen Bond Acceptor Count: 2
• Hydrogen Bond Donor Count: 2
• XLogP3: -1.1

Literature

• Predicting 5-fluorouracil toxicity in colorectal cancer patients from peripheral blood cell telomere length: a multivariate analysis.

  British journal of cancer 20121023

• Phenotyping drug disposition in oncology.

  Cancer treatment reviews 20121001

• Biochemical mapping of human NEIL1 DNA glycosylase and AP lyase activities.

  DNA repair 20120901

• 14th World Congress on Gastrointestinal Cancer.

  The Lancet. Oncology 20120801

• Dihydropyrimidine dehydrogenase (DPD) expression is negatively regulated by certain microRNAs in human lung tissues.

  Lung cancer (Amsterdam, Netherlands) 20120701

• The effect of chemotherapy or radiotherapy on thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in cancer of the uterine cervix.

  European journal of obstetrics, gynecology, and reproductive biology 20120701

• Pretherapeutic uracil and dihydrouracil levels of colorectal cancer patients are associated with sex and toxic side effects during adjuvant 5-fluorouracil-based chemotherapy.

  Cancer 20120601

• Role of thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expressions in gallbladder carcinoma.

  Surgery today 20120601

• Identification of aryl dihydrouracil derivatives as palm initiation site inhibitors of HCV NS5B polymerase.

  Bioorganic & medicinal chemistry letters 20120601

• Expression of dihydropyrimidine dehydrogenase, orotate phosphoribosyl transferase and thymidylate synthase in patients with primary colorectal cancer, and associations with site of first metastasis.

  Anticancer research 20120601

• TS and DPD mRNA levels on formalin-fixed paraffin-embedded specimens as predictors for distant recurrence of rectal cancer treated with preoperative chemoradiotherapy.

  Journal of surgical oncology 20120501

• Expression levels of thymidylate synthase, dihydropyrimidine dehydrogenase, and thymidine phosphorylase in patients with colorectal cancer.

  Anticancer research 20120501

• [Two cases of advanced gastric cancer with peritonitis carcinomatosa that showed disappearance of ascites and obtained a good quality of life by using DIF and paclitaxel].

  Gan to kagaku ryoho. Cancer & chemotherapy 20120401

• Evaluation of 5-fluorouracil pharmacokinetics in cancer patients with a c.1905+1G>A mutation in DPYD by means of a Bayesian limited sampling strategy.

  Clinical pharmacokinetics 20120301

• Polymorphisms of dihydropyrimidine dehydrogenase gene and clinical outcomes of gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy in Chinese population.

  Chinese medical journal 20120301

• Roles of thymidylate synthase and dihydropyrimidine dehydrogenase expression in blood as predictors of response to multimodal therapy in esophageal cancer.

  Surgery 20120201

• A rapid HPLC-ESI-MS/MS method for determination of dihydrouracil/uracil ratio in plasma: evaluation of toxicity to 5-flurouracil in patients with gastrointestinal cancer.

  Therapeutic drug monitoring 20120201

• 1-[(Cyclo-propyl-meth-oxy)meth-yl]-6-(3,4-dimeth-oxy-benzyl)-5-ethyl-1,2,3,4-tetra-hydro-pyrimidine-2,4-dione ethanol hemisolvate.

  Acta crystallographica. Section E, Structure reports online 20120201

• X-ray cross-complementing group 1 and thymidylate synthase polymorphisms might predict response to chemoradiotherapy in rectal cancer patients.

  International journal of radiation oncology, biology, physics 20120101

• Impact of SHMT1 polymorphism on the clinical outcome of patients with metastatic colorectal cancer treated with first-line FOLFIRI+bevacizumab.

  Pharmacogenetics and genomics 20120101

• Role of thymidylate synthase and dihydropyrimidine dehydrogenase mRNA in intrahepatic cholangiocarcinoma.

  Surgery today 20120101

• Assessment of plasma uracil-to-dihydrouracil concentration ratio as an indicator of dihydropyrimidine dehydrogenase activity in clinically normal dogs and dogs with neoplasia or renal insufficiency.

  American journal of veterinary research 20120101

• Involvement of target gene polymorphisms in 5-Fluorouracil toxicity: a case report.

  Pharmacology 20120101

• Effects of depletion of dihydropyrimidine dehydrogenase on focus formation and RPA phosphorylation.

  Journal of radiation research 20120101

• Validation of an ultra-high performance liquid chromatography tandem mass spectrometric method for quantifying uracil and 5,6-dihydrouracil in human plasma.

  Journal of chromatographic science 20120101

• Expression of thymidylate synthase, orotate phosphoribosyltransferase and dihydropyrimidine dehydrogenase in thymic epithelial tumors.

  Lung cancer (Amsterdam, Netherlands) 20111201

• Pharmacokinetics of orally administered uracil in healthy volunteers and in DPD-deficient patients, a possible tool for screening of DPD deficiency.

  Cancer chemotherapy and pharmacology 20111201

• Chromosome 1p21.3 microdeletions comprising DPYD and MIR137 are associated with intellectual disability.

  Journal of medical genetics 20111201

• Gene expression of enzymes required for the de novo synthesis and degradation of pyrimidines in rat peripheral tissues and brain.

  Nucleosides, nucleotides & nucleic acids 20111201

• 15N and 13C{14N} NMR investigation of the major nitrogen-containing segment in an aquatic fulvic acid: evidence for a hydantoin derivative.

  Magnetic resonance in chemistry : MRC 20111201

• Low dihydropyrimidine dehydrogenase correlates with prolonged survival in patients with lung adenocarcinoma treated with 5-fluorouracil.

  Anticancer research 20111201

• Hemizygous deletions on chromosome 1p21.3 involving the DPYD gene in individuals with autism spectrum disorder.

  Clinical genetics 20111101

• Severe fluoropyrimidine-related toxicity: clinical implications of DPYD analysis and UH2/U ratio evaluation.

  Cancer chemotherapy and pharmacology 20111101

• Pyrimidine degradation influences germination seedling growth and production of Arabidopsis seeds.

  Journal of experimental botany 20111101

• mRNA gene expression correlates with histologically diagnosed chemotherapy-induced hepatic injury.

  HPB : the official journal of the International Hepato Pancreato Biliary Association 20111101

• [The Relationship between the efficacy of mFOLFOX6 treatment and the expression of TS, DPD, TP, and ERCC-1 in unresectable colorectal cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20111101

• A new generation of crystallographic validation tools for the protein data bank.

  Structure (London, England : 1993) 20111012

• Expression of thymidylate synthase and dihydropyrimidine dehydrogenase in primary oral squamous cell carcinoma and corresponding metastases in cervical lymph nodes: association with the metastasis suppressor CD82.

  Anticancer research 20111001

• 5-FU-induced neurotoxicity in cancer patients with profound DPD deficiency syndrome: a report of two cases.

  Cancer chemotherapy and pharmacology 20110901

• Gimeracil, an inhibitor of dihydropyrimidine dehydrogenase, inhibits the early step in homologous recombination.

  Cancer science 20110901

• Genetic profiling of GSTP1, DPYD, FCGR2A, FCGR3A and CCND1 genes in an Argentinian population.

  Clinical biochemistry 20110901

• Thymidylate synthase, dihydropyrimidine dehydrogenase, thymidine phosphorylase, orotate phosphoribosyltransferase mRNA expression in lung cancer metastatic lymph node samples obtained by endobronchial ultrasound-guided transbronchial needle aspiration: a pilot study.

  Clinical lung cancer 20110901

• SNPs and Haplotypes in DPYD and Outcome of Capecitabine-Letter.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20110901

• SNPs and haplotypes in DPYD and outcome of capecitabine--Letter.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20110901

• The association of polymorphisms in 5-fluorouracil metabolism genes with outcome in adjuvant treatment of colorectal cancer.

  Pharmacogenomics 20110901

• Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity.

  Pharmacogenomics 20110901

• The therapeutic efficacy of S-1 against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice.

  Cancer chemotherapy and pharmacology 20110801

• Determination of 5-fluorouracil and dihydrofluorouracil levels by using a liquid chromatography-tandem mass spectrometry method for evaluation of dihydropyrimidine dehydrogenase enzyme activity.

  Cancer chemotherapy and pharmacology 20110801

• Prognostic impact of dihydropyrimidine dehydrogenase expression on pancreatic adenocarcinoma patients treated with S-1-based adjuvant chemotherapy after surgical resection.

  Journal of surgical oncology 20110801

• Antitumor effect of Croatian propolis as a consequence of diverse sex-related dihydropyrimidine dehydrogenase (DPD) protein expression.

  Phytomedicine : international journal of phytotherapy and phytopharmacology 20110715

• Thymidylate synthase and dihydropyrimidine dehydrogenase expression levels are associated with response to S-1 plus carboplatin in advanced non-small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20110701

• Genetic effects and modifiers of radiotherapy and chemotherapy on survival in pancreatic cancer.

  Pancreas 20110701

• Delayed repair of radiation induced clustered DNA damage: friend or foe?

  Mutation research 20110603

• Impact of intratumoral thymidylate synthase expression on prognosis after surgical resection for ampullary carcinoma.

  Journal of surgical oncology 20110601

• A mild phenotype of dihydropyrimidine dehydrogenase deficiency and developmental retardation associated with a missense mutation affecting cofactor binding.

  Clinical biochemistry 20110601

• Efficacy and toxicity of S-1 plus cisplatin combination neoadjuvant chemotherapy in patients with oral cancer.

  Gan to kagaku ryoho. Cancer & chemotherapy 20110601

• Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20110515

• The achievement of mass balance by simultaneous quantification of floxuridine prodrug, floxuridine, 5-fluorouracil, 5-dihydrouracil, α-fluoro-β-ureidopropionate, α-fluoro-β-alanine using LC-MS.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20110415

• [Dihydropyrimidine dehydrogenase and thymidine phosphorylase as a prognostic factor of colorectal cancer patients].

  Nihon rinsho. Japanese journal of clinical medicine 20110401

• Hepatic fibrosis does not affect the pharmacokinetics of 5-fluorouracil in rats.

  Biopharmaceutics & drug disposition 20110301

• Thymidilate synthase expression predicts longer survival in patients with stage II colon cancer treated with 5-flurouracil independently of microsatellite instability.

  Journal of cancer research and clinical oncology 20110201

• A pilot study of mRNA expressions of 5-fluorouracil pathway genes in peripheral blood mononuclear cells and tumor tissues in patients with lung adenocarcinoma.

  Lung cancer (Amsterdam, Netherlands) 20110201

• The cancer stem cell marker CD133 is a predictor of the effectiveness of S1+ pegylated interferon α-2b therapy against advanced hepatocellular carcinoma.

  Journal of gastroenterology 20110201

• Relationship between gene expression of 5-fluorouracil metabolic enzymes and 5-fluorouracil sensitivity in primary cancer cells isolated from malignant ascites.

  Cancer investigation 20110201

• 5-Fluorouracil pharmacogenomics: still rocking after all these years?

  Pharmacogenomics 20110201

• A phase I study evaluating the effect of CDHP as a component of S-1 on the pharmacokinetics of 5-fluorouracil.

  Anticancer research 20110201

• DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment efficacy and toxicity.

  Cancer chemotherapy and pharmacology 20110101

• Phase II study of preoperative radiation plus concurrent daily tegafur-uracil (UFT) with leucovorin for locally advanced rectal cancer.

  BMC cancer 20110101

• Quantitative analysis of the enzymes associated with 5-fluorouracil metabolism in prostate cancer biopsies.

  Methods in molecular biology (Clifton, N.J.) 20110101

• New insights in the removal of the hydantoins, oxidation product of pyrimidines, via the base excision and nucleotide incision repair pathways.

  PloS one 20110101

• Severe encephalopathy, lactic acidosis, vegetative instability and neuropathy with 5-Fluorouracil treatment - pyrimidine degradation defect or beriberi?

  Case reports in oncology 20110101

• Is mitochondrial tRNA(phe) variant m.593T>C a synergistically pathogenic mutation in Chinese LHON families with m.11778G>A?

  PloS one 20110101

• Investigation by imaging mass spectrometry of biomarker candidates for aging in the hair cortex.

  PloS one 20110101

• Predicting biological functions of compounds based on chemical-chemical interactions.

  PloS one 20110101

• Standard-dose tegafur combined with uracil is not safe treatment after severe toxicity from 5-fluorouracil or capecitabine.

  Annals of internal medicine 20101207

• Synergistic antitumor activity of the SN-38-incorporating polymeric micelles NK012 with S-1 in a mouse model of non-small cell lung cancer.

  International journal of cancer 20101201

• The mitochondrial genome of the butterfly Papilio xuthus (Lepidoptera: Papilionidae) and related phylogenetic analyses.

  Molecular biology reports 20101201

• Ethylene glycol monomethyl ether-induced toxicity is mediated through the inhibition of flavoprotein dehydrogenase enzyme family.

  Toxicological sciences : an official journal of the Society of Toxicology 20101201

• Insights into the mechanism of dihydropyrimidine dehydrogenase from site-directed mutagenesis targeting the active site loop and redox cofactor coordination.

  Biochimica et biophysica acta 20101201

• Multicenter phase II trial of S-1 in patients with cytokine-refractory metastatic renal cell carcinoma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20101201

• Molecular predictive and prognostic markers in colon cancer.

  Cancer treatment reviews 20101101

• Intragenic deletions and a deep intronic mutation affecting pre-mRNA splicing in the dihydropyrimidine dehydrogenase gene as novel mechanisms causing 5-fluorouracil toxicity.

  Human genetics 20101101

• Contribution of thymidylate synthase to gemcitabine therapy for advanced pancreatic cancer.

  Pancreas 20101101

• Analysis of 5-fluorouracil-related enzymes in pulmonary neuroendocrine carcinoma: differences in biological properties compared to epithelial carcinoma.

  Clinical lung cancer 20101101

• [Four resected cases with basaloid carcinoma of esophagus--comparison of 5-FU-related enzymes (thymidylate synthase (TS), dihydropyrimidine dehydrogenase (DPD), orotate phosphoribosyl transferase (OPRT)) between basaloid carcinoma and squamous cell carcinoma].

  Gan to kagaku ryoho. Cancer & chemotherapy 20101101

• Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20101020

• Thymidine phosphorylase to dihydropyrimidine dehydrogenase ratio as a predictive factor of response to preoperative chemoradiation with capecitabine in patients with advanced rectal cancer.

  Journal of surgical oncology 20101001

• Routine dihydropyrimidine dehydrogenase testing for anticipating 5-fluorouracil-related severe toxicities: hype or hope?

  Clinical colorectal cancer 20101001

• Pharmacogenetics of drug metabolizing enzymes and transporters: effects on pharmacokinetics and pharmacodynamics of anticancer agents.

  Anti-cancer agents in medicinal chemistry 20101001

• A predictive factor for the response to S-1 plus cisplatin in gastric cancer.

  World journal of gastroenterology 20100928

• Germline genetic variation, cancer outcome, and pharmacogenetics.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100910

• Low thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase mRNA expression correlate with prolonged survival in resected non-small-cell lung cancer.

  Clinical lung cancer 20100901

• Absence of large intragenic rearrangements in the DPYD gene in a large cohort of colorectal cancer patients treated with 5-FU-based chemotherapy.

  British journal of clinical pharmacology 20100801

• Lethal outcome of 5-fluorouracil infusion in a patient with a total DPD deficiency and a double DPYD and UTG1A1 gene mutation.

  British journal of clinical pharmacology 20100801

• Pharmacogenetic testing to predict serious toxicity from 5-fluorouracil (5-FU) for patients administered 5-FU-based chemotherapy for cancer.

  Technology Evaluation Center Assessment Program. Executive summary 20100801

• Enhanced 5-fluorouracil cytotoxicity in high cyclooxygenase-2 expressing colorectal cancer cells and xenografts induced by non-steroidal anti-inflammatory drugs via downregulation of dihydropyrimidine dehydrogenase.

  Cancer chemotherapy and pharmacology 20100701

• Validation of an isocratic HPLC method to detect 2-fluoro-beta-alanine for the analysis of dihydropyrimidine dehydrogenase activity.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20100701

• Genetic variation in TYMS in the one-carbon transfer pathway is associated with ovarian carcinoma types in the Ovarian Cancer Association Consortium.

  Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 20100701

• Crystallization and preliminary X-ray analysis of human endonuclease 1 (APE1) in complex with an oligonucleotide containing a 5,6-dihydrouracil (DHU) or an alpha-anomeric 2'-deoxyadenosine (alphadA) modified base.

  Acta crystallographica. Section F, Structural biology and crystallization communications 20100701

• [Correlation between clinicopathological factors and enzymatic activity of orotate phosphoribosyl transferase (OPRT), dihydropyrimidine dehydrogenase (DPD) in esophageal cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20100701

• [Selection of anticancer drug for poorly-differentiated adenocarcinoma of colorectum from the level of orotate phosphoribosyl transferase and dihydropyrimidine dehydrogenase activities in cancer tissue].

  Gan to kagaku ryoho. Cancer & chemotherapy 20100701

• Unilateral hand-foot syndrome: an extraordinary side effect of capecitabine.

  Cutaneous and ocular toxicology 20100601

• Dihydropyrimidine dehydrogenase deficiency caused by a novel genomic deletion c.505_513del of DPYD.

  Nucleosides, nucleotides & nucleic acids 20100601

• [Immunohistochemical and clinicopathological study of thymidylate synthase, dihydropyrimidine dehydrogenase, and orotate phosphoribosyl transferase expression in oral cancer patients responding to UFT].

  Gan to kagaku ryoho. Cancer & chemotherapy 20100601

• Investigation of IVS14 + 1G > A polymorphism of DPYD gene in a group of Bosnian patients treated with 5-Fluorouracil and capecitabine.

  Bosnian journal of basic medical sciences 20100501

• Erlotinib in combination with capecitabine (5'dFUR) in resistant pancreatic cancer cell lines.

  Journal of chemotherapy (Florence, Italy) 20100401

• Synthesis of dihydrouracils spiro-fused to pyrrolidines: druglike molecules based on the 2-arylethyl amine scaffold.

  Molecules (Basel, Switzerland) 20100330

• Coupling of the nucleotide incision and 3'-->5' exonuclease activities in Escherichia coli endonuclease IV: Structural and genetic evidences.

  Mutation research 20100301

• Evaluation of 5-fluorouracil related genes in breast cancer to predict the effect of adjuvant therapy with oral fluorouracil derivatives.

  Oncology reports 20100301

• [Severe toxicity following capecitabine administration because of dihydropyrimidine deshydrogenase (DPD) deficiency].

  Gastroenterologie clinique et biologique 20100301

• Hydrolytic deamination of 5,6-dihydrocytosine in a protic medium: a theoretical study.

  The journal of physical chemistry. A 20100204

• Synergistic effect of 5-fluorouracil and the flavanoid oroxylin A on HepG2 human hepatocellular carcinoma and on H22 transplanted mice.

  Cancer chemotherapy and pharmacology 20100201

• Two cases of 5-fluorouracil toxicity linked with gene variants in the DPYD gene.

  Clinical biochemistry 20100201

• Clinical significance of dihydropyrimidine dehydrogenase and thymidylate synthase expression in patients with pancreatic cancer.

  International journal of clinical oncology 20100201

• The contribution of deleterious DPYD gene sequence variants to fluoropyrimidine toxicity in British cancer patients.

  Cancer chemotherapy and pharmacology 20100101

• Interaction between capecitabine and brivudin in a patient with breast cancer.

  Nature reviews. Clinical oncology 20100101

• UFT and S-1 for treatment of primary lung cancer.

  General thoracic and cardiovascular surgery 20100101

• Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients.

  British journal of clinical pharmacology 20100101

• [Severe bone marrow suppression during adjuvant chemotherapy for gastric cancer by S-1 and its possible relationship to dihydropyrimidine dehydrogenase deficiency].

  Gan to kagaku ryoho. Cancer & chemotherapy 20100101

• [Dihydropyrimidine dehydrogenase deficiency and toxicity to fluoropyrimidine].

  Annales de biologie clinique 20100101

• Dihydropyrimidinase deficiency: Phenotype, genotype and structural consequences in 17 patients.

  Biochimica et biophysica acta 20100101

• Correlations of clinicopathological factors with protein expression levels of thymidylate synthase, dihydropyrimidine dehydrogenase and orotate phosphoribosyltransferase in colorectal cancer.

  Chemotherapy 20100101

• Promoter methylation and large intragenic rearrangements of DPYD are not implicated in severe toxicity to 5-fluorouracil-based chemotherapy in gastrointestinal cancer patients.

  BMC cancer 20100101

• Variants in the dihydropyrimidine dehydrogenase, methylenetetrahydrofolate reductase and thymidylate synthase genes predict early toxicity of 5-fluorouracil in colorectal cancer patients.

  The Journal of international medical research 20100101

• [Pharmacogenomics and chemotherapy].

  Recenti progressi in medicina 20100101

• The value of dihydrouracil/uracil plasma ratios in predicting 5-fluorouracil-related toxicity in colorectal cancer patients.

  The Journal of international medical research 20100101

• Early Steps in the DNA Base Excision Repair Pathway of a Fission Yeast Schizosaccharomyces pombe.

  Journal of nucleic acids 20100101

• Molecular mechanisms of ultraviolet radiation-induced DNA damage and repair.

  Journal of nucleic acids 20100101

• Where should the specimen be excised for the chemosensitivity of colorectal cancer to 5-fluorouracil?

  Hepato-gastroenterology 20100101

• Effect of dimethylnitrosamine-induced liver dysfunction on the pharmacokinetics of 5-fluorouracil after administration of S-1, an antitumour drug, to rats.

  The Journal of pharmacy and pharmacology 20091201

• Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20091120

• Pharmacokinetically guided dose adjustment of 5-fluorouracil: a rational approach to improving therapeutic outcomes.

  Journal of the National Cancer Institute 20091118

• Heavy metal ions affect the activity of DNA glycosylases of the fpg family.

  Biochemistry. Biokhimiia 20091101

• [Expression of dihydropyrimidine dehydrogenase in primary colorectal cancer and liver metastasis--a relationship between mRNA levels in cancer cells and protein levels in cancerous tissue and effect of 5-fluorouracil].

  Gan to kagaku ryoho. Cancer & chemotherapy 20091101

• Microdissection is essential for gene expression analysis of irradiated rectal cancer tissues.

  Oncology reports 20091001

• The dihydrouracil/uracil ratio in plasma, clinical and genetic analysis for screening of dihydropyrimidine dehydrogenase deficiency in colorectal cancer patients treated with 5-fluorouracil.

  Pathologie-biologie 20090901

• The effect of neoadjuvant therapy on the 5-fluorouracil metabolic and relative enzymes of oral squamous cell carcinoma.

  Oncology reports 20090901

• Prognostication of pancreatic adenocarcinoma by expression of thymidine phosphorylase/dihydropyrimidine dehydrogenase ratio and its correlation with survival.

  Expert opinion on drug safety 20090901

• Lack of large intragenic rearrangements in dihydropyrimidine dehydrogenase (DPYD) gene in fluoropyrimidine-treated patients with high-grade toxicity.

  Cancer chemotherapy and pharmacology 20090801

• Circadian variation in intestinal dihydropyrimidine dehydrogenase (DPD) expression: a potential mechanism for benefits of 5FU chrono-chemotherapy.

  Surgery 20090801

• Co-inhibition of cyclooxygenase-2 and dihydropyrimidine dehydrogenase by non-steroidal anti-inflammatory drugs in tumor cells and xenografts.

  Anticancer research 20090801

• African swine fever virus AP endonuclease is a redox-sensitive enzyme that repairs alkylating and oxidative damage to DNA.

  Virology 20090720

• Pharmacokinetics of 5-fluorouracil in elderly Japanese patients with cancer treated with S-1 (a combination of tegafur and dihydropyrimidine dehydrogenase inhibitor 5-chloro-2,4-dihydroxypyridine).

  Drug metabolism and disposition: the biological fate of chemicals 20090701

• A functional analysis of the pyrimidine catabolic pathway in Arabidopsis.

  The New phytologist 20090701

• Predictive and prognostic markers for the outcome of chemotherapy in advanced colorectal cancer, a retrospective analysis of the phase III randomised CAIRO study.

  European journal of cancer (Oxford, England : 1990) 20090701

• Expression of thymidine phosphorylase and dihydropyrimidine dehydrogenase in human breast carcinoma cells and tissues.

  Anticancer research 20090701

• Analysis of severely affected patients with dihydropyrimidine dehydrogenase deficiency reveals large intragenic rearrangements of DPYD and a de novo interstitial deletion del(1)(p13.3p21.3).

  Human genetics 20090601

• Preparation of short interfering RNA containing the modified nucleosides 2-thiouridine, pseudouridine, or dihydrouridine.

  Current protocols in nucleic acid chemistry 20090601

• Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment.

  Pharmacogenomics 20090601

• Complete remission of multiple recurrent hepatocellular carcinomas by oral administration of enteric-coated tegafur/uracil in a patient with huge hepatocellular carcinoma extending to the inferior vena cava after hepatic resection: analysis of mRNA expression of fluoropyrimidine metabolism enzymes in the primary tumor.

  International journal of clinical oncology 20090601

• Pharmacogenetics of fluoropyrimidine and cisplatin. A future application to gastric cancer treatment.

  Journal of gastroenterology and hepatology 20090601

• A combined pharmacokinetic-pharmacodynamic (PK-PD) model for tumor growth in the rat with UFT administration.

  Journal of pharmaceutical sciences 20090501

• Dihydropyrimidine dehydrogenase mRNA expression in peripheral blood of rectal cancer patients is significantly associated with residual tumor and distant metastases following resection.

  Journal of surgical oncology 20090401

• Expression of 5-fluorouracil-related enzymes in lung cancer: ELISA characterizes enzyme activity and messenger RNA expression.

  Oncology reports 20090401

• [Significance of urinary uracil measurement following administration of DPD inhibitory fluoropyrimidine(DIF)products].

  Gan to kagaku ryoho. Cancer & chemotherapy 20090401

• Effects of cepharanthine alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice.

  Anticancer research 20090401

• Cardiotoxicity of 5-fluorouracil and capecitabine in a pancreatic cancer patient with a novel mutation in the dihydropyrimidine dehydrogenase gene.

  JOP : Journal of the pancreas 20090309

• Blood-brain barrier efflux transport of pyrimidine nucleosides and nucleobases in the rat.

  Neurochemical research 20090301

• Molecular determinants of efficacy for 5-FU-based treatments in advanced colorectal cancer: mRNA expression for 18 chemotherapy-related genes.

  International journal of cancer 20090301

• [Clinical significance of intratumoral TS levels and DPD activity in breast cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20090301

• Combined evaluation of dihydropyrimidine dehydrogenase and thymidine phosphorylate mRNA levels in tumor predicts the histopathological effect of 5-fluorouracil-based chemoradiotherapy.

  Cancer letters 20090218

• The role of dihydropyrimidine dehydrogenase expression in resistance to 5-fluorouracil in head and neck squamous cell carcinoma cells.

  Oral oncology 20090201

• Using Q-RT-PCR to measure cyclin D1, TS, TP, DPD, and Her-2/neu as predictors for response, survival, and recurrence in patients with esophageal squamous cell carcinoma following radiochemotherapy.

  International journal of colorectal disease 20090101

• Pharmacokinetics, a main actor in a many-sided approach to severe 5-FU toxicity prediction.

  British journal of clinical pharmacology 20090101

• Metal-triggered changes in the stability and secondary structure of a tetrameric dihydropyrimidinase: a biophysical characterization.

  Biophysical chemistry 20090101

• Comparison of 5-fluorouracil-related gene expression levels between adenocarcinomas and squamous cell carcinomas of the lung.

  Japanese journal of clinical oncology 20090101

• Phase II study of UFT with leucovorin plus hepatic arterial infusion with irinotecan, 5-fluorouracil and leucovorin for non-resectable liver metastases of colorectal cancer.

  Chemotherapy 20090101

• Overexpression of orotate phosphoribosyl transferase in hormone-refractory prostate cancer.

  Oncology reports 20090101

• The predictive and therapeutic value of thymidine phosphorylase and dihydropyrimidine dehydrogenase in capecitabine (Xeloda)-based chemotherapy for head and neck cancer.

  The Laryngoscope 20090101

• Microsatellite instability in colorectal cancer and association with thymidylate synthase and dihydropyrimidine dehydrogenase expression.

  BMC cancer 20090101

• Pharmacokinetic study of S-1.

  International journal of clinical pharmacology and therapeutics 20090101

• Influence of dihydropyrimidine dehydrogenase gene (DPYD) coding sequence variants on the development of fluoropyrimidine-related toxicity in patients with high-grade toxicity and patients with excellent tolerance of fluoropyrimidine-based chemotherapy.

  Neoplasma 20090101

• Thymidylate synthase and dihydropyrimidine dehydrogenase are upregulated in pancreatic and biliary tract cancers.

  Pathobiology : journal of immunopathology, molecular and cellular biology 20090101

• Histopathological effects of cisplatin, doxorubicin and 5-flurouracil (5-FU) on the liver of male albino rats.

  International journal of biological sciences 20090101

• Reaction of cytosine with bisulfite and hydroxylamine.

  Nucleic acids symposium series (2004) 20090101

• TPMT and DPD polymorphisms: Efficient screening method for Indian patients considering taking Thiopurine and 5-FU drugs.

  Disease markers 20090101

• Expression of the fluoropyrimidine-metabolizing enzymes in bladder cancers as measured by the Danenberg tumor profile.

  Oncology research 20090101

• Synthesis and antimicrobial evaluation of 5-iodopyrimidine analogs.

  Indian journal of pharmaceutical sciences 20090101

• High intratumoral dihydropyrimidine dehydrogenase mRNA levels in pancreatic cancer associated with a high rate of response to S-1.

  Cancer chemotherapy and pharmacology 20081201

• Thymidylate synthase, dihydropyrimidine dehydrogenase, orotate phosphoribosyltransferase mRNA and protein expression levels in solid tumors in large scale population analysis.

  International journal of molecular medicine 20081201

• Successful treatment of advanced gallbladder cancer with an anticancer drug S-1: assessment based on intratumoral gene.

  International journal of clinical oncology 20081201

• [Frequency of the 735G --> A mutation of the 5'-splice donor site of intron 14 of the dihydropyrimidine dehydrogenase gene (DPYD) in residents of Novosibirsk region (Russia) as revealed with fluorescent oligonucleotides].

  Genetika 20081201

• Thymidylate synthase and dihydropyrimidine dehydrogenase levels are associated with response to 5-fluorouracil in Caenorhabditis elegans.

  Molecules and cells 20081031

• Is fluorouracil-induced severe toxicity in DPYD*2A individuals related to sex or to treatment regimen?

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20081020

• [The biological point of view on pharmacogenetics of anticancer agents in colorectal cancer].

  Bulletin du cancer 20081001

• HPLC with UV or mass spectrometric detection for quantifying endogenous uracil and dihydrouracil in human plasma.

  Clinical chemistry 20080901

• Prediction of the effect of capecitabine in gastric cancer by immunohistochemical staining of thymidine phosphorylase and dihydropyrimidine dehydrogenase.

  Anti-cancer drugs 20080901

• The iscS gene deficiency affects the expression of pyrimidine metabolism genes.

  Biochemical and biophysical research communications 20080801

• Effects of combined administration of DPD-inhibitory oral fluoropyrimidine, S-1, plus paclitaxel on gene expressions of fluoropyrimidine metabolism-related enzymes in human gastric xenografts.

  Annals of surgical oncology 20080801

• Dihydropyrimidine dehydrogenases and cytidine-deaminase gene polymorphisms as outcome predictors in resected gastric cancer patients treated with fluoropyrimidine adjuvant chemotherapy.

  Journal of surgical oncology 20080801

• A second pathway to degrade pyrimidine nucleic acid precursors in eukaryotes.

  Journal of molecular biology 20080718

• [Pharmacogenetics in oncology: 5-fluorouracil and the dihydropyrimidine dehydrogenase].

  Deutsche medizinische Wochenschrift (1946) 20080701

• [Genetic polymorphisms related to fluoropyrimidine sensitivity and toxicity].

  Gan to kagaku ryoho. Cancer & chemotherapy 20080701

• Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in Chinese cancer patients.

  Journal of clinical pharmacy and therapeutics 20080601

• Application of metabolomic principles to disorders of nucleotide metabolism reveals new metabolic perturbations.

  Nucleosides, nucleotides & nucleic acids 20080601

• Pharmacokinetics of 5-fluorouracil in patients heterozygous for the IVS14+1G > A mutation in the dihydropyrimidine dehydrogenase gene.

  Nucleosides, nucleotides & nucleic acids 20080601

• Altered dihydropyrimidine dehydrogenase activity associated with mild toxicity in patients treated with 5-fluorouracil containing chemotherapy.

  Nucleosides, nucleotides & nucleic acids 20080601

• Identification of two novel mutations C79X and R235Q in the dihydropyrimidine dehydrogenase gene in a patient presenting with hematuria.

  Nucleosides, nucleotides & nucleic acids 20080601

• Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy.

  Annals of oncology : official journal of the European Society for Medical Oncology 20080501

• Predicting fluorouracil toxicity: can we finally do it?

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080501

• Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080501

• UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma.

  Cancer 20080501

• A carboxylesterase 2 gene polymorphism as predictor of capecitabine on response and time to progression.

  Current drug metabolism 20080501

• Pilot study of combination chemotherapy of S-1, a novel oral DPD inhibitor, and interferon-alpha for advanced hepatocellular carcinoma with extrahepatic metastasis.

  Cancer 20080415

• Expression level of thymidylate synthase mRNA reflects 5-fluorouracil sensitivity with low dose and long duration in primary colorectal cancer.

  Cancer chemotherapy and pharmacology 20080401

• Novel DNA glycosylases from Mycobacterium tuberculosis.

  Biochemistry. Biokhimiia 20080401

• Atypical toxicity associated with 5-Fluororacil in a DPD-deficient patient with pancreatic cancer. Is ethnicity a risk factor?

  JOP : Journal of the pancreas 20080308

• Amidohydrolases of the reductive pyrimidine catabolic pathway purification, characterization, structure, reaction mechanisms and enzyme deficiency.

  Biochimica et biophysica acta 20080301

• Prognostic value of 5-fluorouracil metabolic enzyme genes in Dukes' stage B and C colorectal cancer patients treated with oral 5-fluorouracil-based adjuvant chemotherapy.

  Oncology reports 20080301

• [Significance of pyrimidine nucleoside phosphorylase and dihydropyrimidine dehydrogenase levels to predict postoperative recurrence in primary breast cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20080301

• Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer.

  British journal of cancer 20080226

• [A case of dihydropyrimidine dehydrogenase (DPD) deficiency with severe side effects from UFT/Uzel administration].

  Gan to kagaku ryoho. Cancer & chemotherapy 20080201

• Thymidine phosphorylase and dihydropyrimidine dehydrogenase are predictive factors of therapeutic efficacy of capecitabine monotherapy for breast cancer-preliminary results.

  The journal of medical investigation : JMI 20080201

• Correlation between clinical pathologic factors and activity of 5-FU-metabolizing enzymes in colorectal cancer.

  Journal of Nippon Medical School = Nippon Ika Daigaku zasshi 20080201

• Can inhibiting dihydropyrimidine dehydrogenase limit hand-foot syndrome caused by fluoropyrimidines?

  Clinical cancer research : an official journal of the American Association for Cancer Research 20080101

• Relationship between expression of 5-fluorouracil metabolic enzymes and 5-fluorouracil sensitivity in esophageal carcinoma cell lines.

  Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus 20080101

• Genetic regulation of beta-ureidopropionase and its possible implication in altered uracil catabolism.

  Pharmacogenetics and genomics 20080101

• Pharmacogenomics of drug-metabolizing enzymes and drug transporters in chemotherapy.

  Methods in molecular biology (Clifton, N.J.) 20080101

• 5-Fluorouracil-related gene expression in hepatic artery infusion-treated patients with hepatic metastases from colorectal carcinomas.

  Anticancer research 20080101

• The role of molecular markers in predicting response to therapy in patients with colorectal cancer.

  Molecular diagnosis & therapy 20080101

• 5-Fluorouracil toxicity-attributable IVS14 + 1G > A mutation of the dihydropyrimidine dehydrogenase gene in Polish colorectal cancer patients.

  Pharmacological reports : PR 20080101

• Neurotrophic keratitis in a patient with dihydroxypyrimidine dehydrogenase deficiency.

  Indian journal of ophthalmology 20080101

• Clinical implications of thymidylate synthetase, dihydropyrimidine dehydrogenase and orotate phosphoribosyl transferase activity levels in colorectal carcinoma following radical resection and administration of adjuvant 5-FU chemotherapy.

  BMC cancer 20080101

• [Interactions of human ribosomal protein S3 with undamaged and damaged DNA].

  Molekuliarnaia biologiia 20080101

• Importance of thymidine phosphorylase, dihydropyrimidine dehydrogenase and thymidylate synthase expression at the invasive front of T3 rectal cancer as prognostic factors.

  Hepato-gastroenterology 20080101

• 5-Fluorouracil-related gene expression in primary sites and hepatic metastases of colorectal carcinomas.

  Anticancer research 20080101

• Changes of gene expression of thymidine phosphorylase, thymidylate synthase, dihydropyrimidine dehydrogenase after the administration of 5'-deoxy-5-fluorouridine, paclitaxel and its combination in human gastric cancer xenografts.

  Anticancer research 20080101

• Efficacy of laser capture microdissection plus RT-PCR technique in analyzing gene expression levels in human gastric cancer and colon cancer.

  BMC cancer 20080101

• Quantitative analysis of fluorouracil-related genes in chronic viral hepatitis using microdissection.

  Hepato-gastroenterology 20080101

• X-ray crystallographic identification of bisulfite-uracil adduct as sodium 5,6-dihydrouracil 6-sulfonate.

  Nucleic acids symposium series (2004) 20080101

• Hypermethylation of the DPYD promoter region is not a major predictor of severe toxicity in 5-fluorouracil based chemotherapy.

  Journal of experimental & clinical cancer research : CR 20080101

• Atypical hand-and-foot syndrome in an African American patient treated with capecitabine with normal DPD activity: is there an ethnic disparity?

  Cutaneous and ocular toxicology 20080101

• The discrepancy in thymidylate synthase and dihydropyrimidine dehydrogenase expression depending on measurement methodologies in stage 4 gastric cancer.

  Hepato-gastroenterology 20080101

• Strong association of a common dihydropyrimidine dehydrogenase gene polymorphism with fluoropyrimidine-related toxicity in cancer patients.

  PloS one 20080101

• Thymidylate synthase, dihydropyrimidine dehydrogenase, ERCC1, and thymidine phosphorylase gene expression in primary and metastatic gastrointestinal adenocarcinoma tissue in patients treated on a phase I trial of oxaliplatin and capecitabine.

  BMC cancer 20080101

• Quantitative double-fluorescence immunohistochemistry (qDFIHC), a novel technology to assess protein expression: a pilot study analyzing 5-FU sensitive markers thymidylate synthase, dihydropyrimidine dehydrogenase and orotate phosphoribosyl transferases in gastric cancer tissue specimens.

  Cancer letters 20071208

• Severe or lethal toxicities upon capecitabine intake: is DPYD genetic polymorphism the ideal culprit?

  Trends in pharmacological sciences 20071201

• Gene expression of 5-fluorouracil metabolic enzymes in hepatocellular carcinoma and non-tumor tissue.

  Journal of chemotherapy (Florence, Italy) 20071201

• Long-term survival on capecitabine in two gemcitabine refractory pancreatic cancer patients. Is there a pharmacogenetic explanation?

  JOP : Journal of the pancreas 20071109

• Genetic regulation of dihydropyrimidinase and its possible implication in altered uracil catabolism.

  Pharmacogenetics and genomics 20071101

• Alternative pharmacokinetics of S-1 components, 5-fluorouracil, dihydrofluorouracil and alpha-fluoro-beta-alanine after oral administration of S-1 following total gastrectomy.

  Cancer science 20071001

• Predictive implications of nucleoside metabolizing enzymes in premenopausal women with node-positive primary breast cancer who were randomly assigned to receive tamoxifen alone or tamoxifen plus tegafur-uracil as adjuvant therapy.

  International journal of oncology 20071001

• SSCP screening of the dihydropyrimidine dehydrogenase gene polymorphisms of the Japanese population using a semi-automated electrophoresis unit.

  Biochemical genetics 20071001

• Suicide gene therapy with the yeast fusion gene cytosine deaminase/uracil phosphoribosyltransferase is not enough for pancreatic cancer.

  Pancreas 20071001

• Mutational spectrum of dihydropyrimidine dehydrogenase gene (DPYD) in the Tunisian population.

  Comptes rendus biologies 20071001

• [Orotate phosphoribosyltransferase levels in gastric carcinoma and normal gastric mucosa - correlation with thymidylate synthase and dihydropyrimidine dehydrogenase levels and the changes after neoadjuvant chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20071001

• Synergistic antitumor effect of combined 5-fluorouracil (5-FU) with 5-chloro-2,4-dihydroxypyridine on 5-FU-resistant gastric cancer cells: possible role of a dihydropyrimidine dehydrogenase-independent mechanism.

  Journal of gastroenterology 20071001

• DPYD*2A mutation: the most common mutation associated with DPD deficiency.

  Cancer chemotherapy and pharmacology 20070901

• [Role of pharmacogenetics in chemotherapy of colorectal cancers].

  La Revue de medecine interne 20070901

• Dihydropyrimidine dehydrogenase activity correlates with fluorouracil sensitivity in breast cancer.

  Experimental oncology 20070901

• Regulation of genes of the circadian clock in human colon cancer: reduced period-1 and dihydropyrimidine dehydrogenase transcription correlates in high-grade tumors.

  Cancer research 20070815

• Expression of thymidylate synthase and dihydropyrimidine dehydrogenase in adenoid cystic carcinoma of the head and neck: correlation with clinical outcome.

  Oral oncology 20070801

• Dihydropyrimidine dehydrogenase activity and the IVS14+1G>A mutation in patients developing 5FU-related toxicity.

  British journal of clinical pharmacology 20070801

• Correlation between thymidylate synthase and dihydropyrimidine dehydrogenase mRNA level and in vitro chemosensitivity to 5-fluorouracil, in relation to differentiation in gastric cancer.

  Cancer chemotherapy and pharmacology 20070801

• DPD is a molecular determinant of capecitabine efficacy in colorectal cancer.

  International journal of oncology 20070801

• Alteration of dihydropyrimidine dehydrogenase expression by IFN-alpha affects the antiproliferative effects of 5-fluorouracil in human hepatocellular carcinoma cells.

  Molecular cancer therapeutics 20070801

• Gene cloning, expression, and substrate specificity of an imidase from the strain Pseudomonas putida YZ-26.

  Current microbiology 20070701

• [Expression of mRNA levels of thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase and orotate phosphoribosyltransferase in diffusely infiltrating colorectal cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20070701

• Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression after administration of 5-fluorouracil to patients with colorectal cancer.

  International journal of cancer 20070615

• A case of squamous cell carcinoma of the head and neck producing granulocyte-colony stimulating factor with marked leukocytosis.

  Auris, nasus, larynx 20070601

• Clinical, biochemical and genetic findings in two siblings with a dihydropyrimidinase deficiency.

  Molecular genetics and metabolism 20070601

• Measurement of DPD and TS transcripts aimed to predict clinical benefit from fluoropyrimidines: confirmation of the trend in Russian colorectal cancer series and caution regarding the gene referees.

  Onkologie 20070601

• [Anti-tumor effects of various interferons-alpha +5-fluorouracil via downregulation of dihydropyrimidine dehydrogenase in hepatoma cells].

  Gan to kagaku ryoho. Cancer & chemotherapy 20070601

• Suppression of DPYD expression in RKO cells via DNA methylation in the regulatory region of the DPYD promoter: a potentially important epigenetic mechanism regulating DPYD expression.

  Biochemistry and cell biology = Biochimie et biologie cellulaire 20070601

• Pyrimidine nucleoside phosphorylase and dihydropyrimidine dihydrogenase activities as predictive factors for the efficacy of doxifluridine together with mitomycin C as adjuvant chemotherapy in primary colorectal cancer.

  Hepato-gastroenterology 20070601

• 5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency.

  Cancer letters 20070508

• A case of capecitabine-induced coronary microspasm in a patient with rectal cancer.

  World journal of gastroenterology 20070414

• Should DPD analysis be required prior to prescribing fluoropyrimidines?

  European journal of cancer (Oxford, England : 1990) 20070401

• Thymidylate synthase (TYMS) and dihydropyrimidine dehydrogenase (DPYD) polymorphisms in the Korean population for prediction of 5-fluorouracil-associated toxicity.

  Therapeutic drug monitoring 20070401

• Role of thymidine phosphorylase and orotate phosphoribosyltransferase mRNA expression and its ratio to dihydropyrimidine dehydrogenase in the prognosis and clinicopathological features of patients with pancreatic cancer.

  International journal of clinical oncology 20070401

• Modified Irinotecan/5FU/Leucovorin therapy in advanced colorectal cancer and predicting therapeutic efficacy by expression of tumor-related enzymes.

  Scandinavian journal of gastroenterology 20070401

• Phase II clinical trial of capecitabine in the treatment of advanced, persistent or recurrent squamous cell carcinoma of the cervix with translational research: a gynecologic oncology group study.

  Gynecologic oncology 20070301

• The significance of the expression of dihydropyrimidine dehydrogenase in prostate cancer.

  BJU international 20070301

• Changes to the dihydropyrimidine dehydrogenase gene copy number influence the susceptibility of cancers to 5-FU-based drugs: Data mining of the NCI-DTP data sets and validation with human tumour xenografts.

  European journal of cancer (Oxford, England : 1990) 20070301

• HPLC-electrospray tandem mass spectrometry for rapid determination of dihydropyrimidine dehydrogenase activity.

  Clinical chemistry 20070301

• Regulation of human dihydropyrimidine dehydrogenase: implications in the pharmacogenetics of 5-FU-based chemotherapy.

  Pharmacogenomics 20070301

• Clinical role of orotate phosphoribosyl transferase and dihydropyrimidine dehydrogenase in colorectal cancer treated with postoperative fluoropyrimidine.

  Surgery 20070301

• Thymidine phosphorylase mRNA level predicts survival of patients with advanced oropharyngeal cancer.

  Acta oto-laryngologica 20070301

• FRA1E common fragile site breaks map within a 370kilobase pair region and disrupt the dihydropyrimidine dehydrogenase gene (DPYD).

  Cancer letters 20070208

• The prognostic significance of thymidylate synthase and dihydropyrimidine dehydrogenase in colorectal cancer of 303 patients adjuvantly treated with 5-fluorouracil.

  International journal of cancer 20070201

• Polymorphisms in the thymidylate synthase and dihydropyrimidine dehydrogenase genes predict response and toxicity to capecitabine-raltitrexed in colorectal cancer.

  Oncology reports 20070201

• [The association between DPYD gene polymorphism and chemotherapeutic toxicity of 5-FU in gastric carcinoma and colonic carcinoma].

  Zhonghua nei ke za zhi 20070201

• Pre-steady-state kinetic study of substrate specificity of Escherichia coli formamidopyrimidine--DNA glycosylase.

  Biochemistry 20070116

• Combination therapy of human pancreatic cancer implanted in nude mice by oral fluoropyrimidine anticancer agent (S-1) with interferon-alpha.

  Cancer chemotherapy and pharmacology 20070101

• Identification of a novel mutation in the dihydropyrimidine dehydrogenase gene in a patient with a lethal outcome following 5-fluorouracil administration and the determination of its frequency in a population of 500 patients with colorectal carcinoma.

  Clinical biochemistry 20070101

• Increased dihydropyrimidine dehydrogenase activity associated with mild toxicity in patients treated with 5-fluorouracil and leucovorin.

  European journal of cancer (Oxford, England : 1990) 20070101

• Cyclophosphamide augments the anti-tumor efficacy of uracil and tegafur by inhibiting dihydropyrimidine dehydrogenase.

  Oncology reports 20070101

• The dihydrouracil/uracil ratios in plasma and toxicities of 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer patients.

  Chemotherapy 20070101

• Capecitabine in advanced gastric or oesophagogastric cancer: a viewpoint by Sai-Hong Ignatius Ou and Randall F. Holcombe.

  Drugs 20070101

• Rapid detection of the DPYD IVS14+1G>A mutation for screening patients to prevent fluorouracil-related toxicity.

  Molecular diagnosis & therapy 20070101

• Gene expression profile of 5-fluorouracil metabolic enzymes in primary colorectal cancer: potential as predictive parameters for response to fluorouracil-based chemotherapy.

  Anticancer research 20070101

• [Detection of dihydropyrimidine dehydrogenase deficiency before treatment by fluoropyrimidines].

  Therapie 20070101

• [Pro or con the phenotyping/genotyping of patients treated by 5-Fluorouracil to prevent adverse drug reactions?].

  Therapie 20070101

• [Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer].

  Magyar onkologia 20070101

• Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase expression in tumor tissue, regarding the efficacy of postoperatively administered UFT (tegafur+uracil) in patients with non-small cell lung cancer.

  Anticancer research 20070101

• Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice.

  Anticancer research 20070101

• Phase II study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: up-regulation of thymidine phosphorylase.

  Cancer journal (Sudbury, Mass.) 20070101

• Genetic variations and haplotype structures of the DPYD gene encoding dihydropyrimidine dehydrogenase in Japanese and their ethnic differences.

  Journal of human genetics 20070101

• DPYD*5 gene mutation contributes to the reduced DPYD enzyme activity and chemotherapeutic toxicity of 5-FU: results from genotyping study on 75 gastric carcinoma and colon carcinoma patients.

  Medical oncology (Northwood, London, England) 20070101

• Base excision repair of ionizing radiation-induced DNA damage in G1 and G2 cell cycle phases.

  Cancer cell international 20070101

• Dihydropyrimidine dehydrogenase activity during long-term adjuvant treatment with oral uracil and tegafur for colorectal cancer.

  Chemotherapy 20070101

• Rapid detection of the DPYD IVS14+1G>A mutation for screening patients to prevent fluorouracil-related toxicity.

  Molecular diagnosis & therapy 20070101

• Unbiased characterization of genotype-dependent metabolic regulations by metabolomic approach in Arabidopsis thaliana.

  BMC systems biology 20070101

• Levels and expressions of orotate phosphoribosyltransferase in gastric carcinoma and normal gastric mucosa tissues.

  Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 20070101

• Investigation of IVS14+ 1G > A polymorphism of DPYD gene in a group of Turkish patients with colorectal cancer.

  Anticancer research 20070101

• Radiation recall phenomenon secondary to capecitabine: possible role of thymidine phosphorylase.

  Cancer chemotherapy and pharmacology 20061201

• The expression profiles of orotate phosphoribosyltransferase and dihydropyrimidine dehydrogenase in gastric cancer and their clinical significance.

  Oncology reports 20061201

• Expression of thymidylate synthase and dihydropyrimidine dehydrogenase in oral squamous cell carcinoma: possible markers as predictors of clinical outcome.

  Acta oto-laryngologica 20061201

• Crystallization and preliminary crystallographic studies of the recombinant dihydropyrimidinase from Sinorhizobium meliloti CECT4114.

  Acta crystallographica. Section F, Structural biology and crystallization communications 20061201

• ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20061120

• Thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer and normal mucosa in patients.

  Pharmacogenetics and genomics 20061101

• Origin of informational polymers: The concurrent roles of formamide and phosphates.

  Chembiochem : a European journal of chemical biology 20061101

• [Prediction of sensitivity to 5-fluorouracil (5-fu) by metabolic and target enzyme activities in colon cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20061101

• Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance.

  Molecular cancer therapeutics 20061101

• A case of hepatocellular carcinoma with multiple lung, spleen, and remnant liver metastasis successfully treated by combination chemotherapy with the novel oral DPD-inhibiting chemotherapeutic drug S-1 and interferon-alpha.

  Journal of gastroenterology 20061101

• Profiling dihydropyrimidine dehydrogenase deficiency in patients with cancer undergoing 5-fluorouracil/capecitabine therapy.

  Clinical colorectal cancer 20061101

• Catalytic mechanism of Escherichia coli endonuclease VIII: roles of the intercalation loop and the zinc finger.

  Biochemistry 20061003

• Orotate phosphoribosyl transferase mRNA expression in oral squamous cell carcinoma and its relationship with the dihydropyrimidine dehydrogenase expression and the clinical effect of 5-fluorouracil.

  Oral oncology 20061001

• Expression of chemoresistance-related proteins in alpha-fetoprotein-producing adenocarcinoma of the digestive organs.

  Oncology reports 20061001

• Thymidine phosphorylase levels and dihydropyrimidine dehydrogenase levels in non-small cell lung cancer tissues.

  Oncology reports 20061001

• Peripheral neuropathy exacerbation associated with topical 5-fluorouracil.

  Anti-cancer drugs 20061001

• A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity.

  Clinical pharmacology and therapeutics 20061001

• A mass balance and disposition study of the DNA methyltransferase inhibitor zebularine (NSC 309132) and three of its metabolites in mice.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20061001

• A rapid and inexpensive method for anticipating severe toxicity to fluorouracil and fluorouracil-based chemotherapy.

  Therapeutic drug monitoring 20061001

• Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20060915

• Pharmacogenetics of capecitabine in advanced breast cancer patients.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20060915

• Evaluations of biomarkers associated with 5-FU sensitivity for non-small-cell lung cancer patients postoperatively treated with UFT.

  British journal of cancer 20060904

• Dihydropyrimidine dehydrogenase deficiency in an Indian population.

  Cancer chemotherapy and pharmacology 20060901

• Prognostic value of histologic tumor regression, thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase in rectal cancer UICC Stage II/III after neoadjuvant chemoradiotherapy.

  The American journal of surgical pathology 20060901

• Identification of potentially useful combinations of epidermal growth factor receptor tyrosine kinase antagonists with conventional cytotoxic agents using median effect analysis.

  Anti-cancer drugs 20060901

• Thymidine phosphorylase and capecitabine: a predictive marker for therapy selection?

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060901

• Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060901

• Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060901

• Hand-foot syndrome variant in a dihydropyrimidine dehydrogenase-deficient patient treated with capecitabine.

  Clinical colorectal cancer 20060901

• Synergistic effects of docetaxel and S-1 by modulating the expression of metabolic enzymes of 5-fluorouracil in human gastric cancer cell lines.

  International journal of cancer 20060815

• Toxic death-case after capecitabine + oxaliplatin (XELOX) administration: probable implication of dihydropyrimidine deshydrogenase deficiency.

  Cancer chemotherapy and pharmacology 20060801

• 5-fluorouracil-related gene expression levels in primary colorectal cancer and corresponding liver metastasis.

  International journal of cancer 20060801

• A Phase I study of weekly intravenous oxaliplatin in combination with oral daily capecitabine and radiation therapy in the neoadjuvant treatment of rectal adenocarcinoma.

  International journal of radiation oncology, biology, physics 20060801

• Determinants of chemosensitivity in gastric cancer.

  Current opinion in pharmacology 20060801

• TPMT, UGT1A1 and DPYD: genotyping to ensure safer cancer therapy?

  Trends in pharmacological sciences 20060801

• Capecitabine therapy for refractory metastatic thyroid carcinoma: a case series.

  Thyroid : official journal of the American Thyroid Association 20060801

• [Dihydropyrimidine dehydrogenase activity and its genetic aberrations].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060801

• [Correlative analysis between serum dihydropyrimidine dehydrogenase, activity, concentration of 5-fluorouracil and adverse events in the treatment of advanced gastric cancer patients].

  Ai zheng = Aizheng = Chinese journal of cancer 20060801

• Liquid chromatography-tandem mass spectrometric assay for the analysis of uracil, 5,6-dihydrouracil and beta-ureidopropionic acid in urine for the measurement of the activities of the pyrimidine catabolic enzymes.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20060724

• Predicting 5-fluorouracil chemosensitivity of liver metastases from colorectal cancer using primary tumor specimens: three-gene expression model predicts clinical response.

  International journal of cancer 20060715

• Relationship between p53 status and 5-fluorouracil sensitivity in 3 cell lines.

  Mutation research 20060714

• The relationship between survival and the expression of dihydropyrimidine dehydrogenase in patients with colorectal cancer.

  Oncology reports 20060701

• High-grade and hormone-treated prostate cancer express high levels of thymidylate synthase.

  BJU international 20060701

• [A case of recurrent gastric cancer with dihydropyrimidine dehydrogenase (DPD) deficiency].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060701

• Methyl-group metabolism and the response of colorectal cancer to 5-fluorouracil.

  Critical reviews in oncogenesis 20060701

• Methylation of the DPYD promoter and dihydropyrimidine dehydrogenase deficiency.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20060615

• [Relationships among the expression of thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase and the prognosis of breast cancer].

  Zhonghua yi xue za zhi 20060613

• Thymidylate synthase expression in oral squamous cell carcinoma predicts response to S-1.

  Oncology reports 20060601

• Antitumor effect of combination of S-1 and docetaxel on the human breast cancer xenograft transplanted into SCID mice.

  Oncology reports 20060601

• In vitro sensitivity to platinum-derived drugs is associated with expression of thymidylate synthase and dihydropyrimidine dehydrogenase in human lung cancer.

  Oncology reports 20060601

• [Correlation between clinical pathologic factors and enzymatic activity of orotate Phosphoribosyl transferase (OPRT), Dihydropyrimidine dehydrogenase (DPD) and Thymidylate synthase (TS) in colorectal cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060601

• [Pharmacokinetics of S-1].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060601

• [Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060601

• The crystal structures of dihydropyrimidinases reaffirm the close relationship between cyclic amidohydrolases and explain their substrate specificity.

  The Journal of biological chemistry 20060512

• Antitumor activity of erlotinib in combination with capecitabine in human tumor xenograft models.

  Cancer chemotherapy and pharmacology 20060501

• Individualizing chemotherapeutic treatment of colorectal cancer.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20060501

• [Thymidylate synthase and dihydropyrimidine dehydrogenase expression and histological effects of preoperative UFT in gastric cancer patients].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060501

• The role of Sp1 and Sp3 in the constitutive DPYD gene expression.

  Biochimica et biophysica acta 20060501

• High-performance liquid chromatographic assay with UV detection for measurement of dihydrouracil/uracil ratio in plasma.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20060413

• Thymidine phosphorylase, dihydropyrimidine dehydrogenase and thymidylate synthase mRNA expression in primary colorectal tumors-correlation to tumor histopathology and clinical follow-up.

  International journal of colorectal disease 20060401

• Recurrence and 5-FU sensitivity of stage I/II node-negative breast, lung, or gastric cancer with occult neoplastic cells in lymph node sinuses.

  Oncology reports 20060401

• Correlation between chemosensitivity and mRNA expression level of 5-fluorouracil-related metabolic enzymes during liver metastasis of colorectal cancer.

  Oncology reports 20060401

• Analysis of pyrimidine catabolism in Drosophila melanogaster using epistatic interactions with mutations of pyrimidine biosynthesis and beta-alanine metabolism.

  Genetics 20060301

• Validation of real-time reverse-transcription-polymerase chain reaction for quantification of capecitabine-metabolizing enzymes.

  Analytical biochemistry 20060301

• Screening for dihydropyrimidine dehydrogenase deficiency: to do or not to do, that's the question.

  Cancer investigation 20060301

• Unpredicted severe toxicity after 5-fluorouracil treatment due to dihydropyrimidine dehydrogenase deficiency.

  The Korean journal of internal medicine 20060301

• [Prediction of treatment outcome after adjuvant loco-regional chemotherapy following liver resection for colorectal metastases--preliminary results].

  Rozhledy v chirurgii : mesicnik Ceskoslovenske chirurgicke spolecnosti 20060301

• Plasma level of a 5-fluorouracil metabolite, fluoro-beta-alanine correlates with dihydropyrimidine dehydrogenase activity of peripheral blood mononuclear cells in 5-fluorouracil treated patients.

  Journal of experimental & clinical cancer research : CR 20060301

• Quantitative determination of zebularine (NSC 309132), a DNA methyltransferase inhibitor, and three metabolites in murine plasma by high-performance liquid chromatography coupled with on-line radioactivity detection.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20060202

• Molecular factors of 5-fluorouracil metabolism in colorectal cancer: analysis of primary tumor and lymph node metastasis.

  International journal of oncology 20060201

• Influence of chemotherapeutic agents and cytokines on the expression of 5-fluorouracil-associated enzymes in human colon cancer cell lines.

  Journal of gastroenterology 20060201

• Diamine oxidase, a plasma biomarker in rats to GI tract toxicity of oral fluorouracil anti-cancer drugs.

  Toxicology 20060116

• The uracil breath test in the assessment of dihydropyrimidine dehydrogenase activity: pharmacokinetic relationship between expired 13CO2 and plasma [2-13C]dihydrouracil.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20060115

• Genetic testing for pharmacogenetics and its clinical application in drug therapy.

  Clinica chimica acta; international journal of clinical chemistry 20060101

• Phase II study of tailored chemotherapy for advanced colorectal cancer with either 5-fluouracil and leucovorin or oxaliplatin and irinotecan based on the expression of thymidylate synthase and dihydropyrimidine dehydrogenase.

  Annals of oncology : official journal of the European Society for Medical Oncology 20060101

• Upregulation of thymidine phosphorylase in rectal cancer tissues by mitomycin C.

  Journal of surgical oncology 20060101

• Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer.

  Clinical pharmacokinetics 20060101

• Purification, crystallization and X-ray diffraction analysis of dihydropyrimidinase from Dictyostelium discoideum.

  Acta crystallographica. Section F, Structural biology and crystallization communications 20060101

• Is capecitabine safe in patients with gastrointestinal cancer and dihydropyrimidine dehydrogenase deficiency?

  Clinical colorectal cancer 20060101

• Thymidine phosphorylase and dihydropyrimidine dehydrogenase expression levels in tumor and normal tissue specimens of T3 human colorectal carcinoma.

  Surgery today 20060101

• Pyrimidine base supplementation effects curdlan production in Agrobacterium sp. ATCC 31749.

  Journal of basic microbiology 20060101

• Thymidylate synthase and dihydropyrimidine dehydrogenase expressions in gallbladder cancer.

  Anticancer research 20060101

• How may anticancer chemotherapy with fluorouracil be individualised?

  Clinical pharmacokinetics 20060101

• Thymidylate synthase and dihydropyrimidine dehydrogenase are related to histological effects of 5-fluorouracil and cisplatin neoadjuvant chemotherapy for primary gastric cancer patients.

  Cancer investigation 20060101

• Methylenetetrahydrofolate reductase C677T is not associated with expression of pyrimidine metabolic enzyme genes in colorectal cancer.

  The Journal of international medical research 20060101

• Prediction of clinical outcome of fluoropyrimidine-based chemotherapy for gastric cancer patients, in terms of the 5-fluorouracil metabolic pathway.

  Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 20060101

• Efficacy of S-1 for patients with peritoneal metastasis of gastric cancer.

  Chemotherapy 20060101

• A neonate with recurrent vomiting and generalized hypotonia diagnosed with a deficiency of dihydropyrimidine dehydrogenase.

  Nucleosides, nucleotides & nucleic acids 20060101

• A pivotal role for beta-aminoisobutyric acid and oxidative stress in dihydropyrimidine dehydrogenase deficiency?

  Nucleosides, nucleotides & nucleic acids 20060101

• Pharmacokinetic modelling of [2-13C]uracil metabolism in normal and DPD-deficient dogs.

  Nucleosides, nucleotides & nucleic acids 20060101

• Activity of pyrimidine degradation enzymes in normal tissues.

  Nucleosides, nucleotides & nucleic acids 20060101

• Determination of 5-fluorouracil in plasma with HPLC-tandem mass spectrometry.

  Nucleosides, nucleotides & nucleic acids 20060101

• Correlation between the urinary dihydrouracil-uracil ratio and the 5-FU plasma concentration in patients treated with oral 5-FU analogs.

  Anticancer research 20060101

• Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.

  Oncology 20060101

• Expression of genes for 5-FU-metabolizing enzymes and response to irinotecan plus 5-FU-leucovorin in colorectal cancer.

  Anticancer research 20060101

• Methylation of the DPYD promoter: an alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20051215

• Antitumor efficacy of capecitabine and celecoxib in irradiated and lead-shielded, contralateral human BxPC-3 pancreatic cancer xenografts: clinical implications of abscopal effects.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20051215

• Recurrence and 5-FU sensitivity of stage II/III node-positive gastric cancer with occult neoplastic cells in lymph node sinuses.

  Oncology reports 20051201

• Physiologically based pharmacokinetic modelling of the three-step metabolism of pyrimidine using C-uracil as an in vivo probe.

  British journal of clinical pharmacology 20051201

• Phase I study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: expression analysis of genes related to outcome.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20051201

• TYMS and DPYD polymorphisms in a Turkish population.

  European journal of clinical pharmacology 20051201

• Recurrence and 5-FU sensitivity of stage III/Dukes' C colorectal cancer with occult neoplastic cells in lymph node sinuses.

  Oncology reports 20051101

• Recurrence and 5-FU sensitivity of stage II/Dukes' B colorectal cancer with occult neoplastic cells in lymph node sinuses.

  Oncology reports 20051101

• Immunohistochemical demonstration of fluoropyrimidine-metabolizing enzymes in various types of cancer.

  Oncology reports 20051101

• [Genetic alterations and chemoresistance].

  Gan to kagaku ryoho. Cancer & chemotherapy 20051101

• [Polygenetic pharmacogenomic strategies to identify drug sensitivity biomarkers].

  Gan to kagaku ryoho. Cancer & chemotherapy 20051101

• [Expression of mRNA levels of thymidylate synthase, dihydropyrimidine dehydrogenase, and orotate phosphoribosyltransferase of colorectal cancer--relationships among mRNA levels in association with response to 5-FU based treatment].

  Gan to kagaku ryoho. Cancer & chemotherapy 20051101

• A series of 5-(5,6)-dihydrouracil substituted 8-hydroxy-[1,6]naphthyridine-7-carboxylic acid 4-fluorobenzylamide inhibitors of HIV-1 integrase and viral replication in cells.

  Bioorganic & medicinal chemistry letters 20051015

• Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase protein expression on survival in adjuvantly treated stage III colon cancer patients.

  Annals of oncology : official journal of the European Society for Medical Oncology 20051001

• Immunohistochemical analysis of thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase in rectal cancer (cUICC II/III): correlation with histopathologic tumor regression after 5-fluorouracil-based long-term neoadjuvant chemoradiotherapy.

  The American journal of surgical pathology 20051001

• Genetic determinants of cancer drug efficacy and toxicity: practical considerations and perspectives.

  Anti-cancer drugs 20051001

• [Clinicopathological significance of pyrimidine nucleoside phosphorylase (PyNPase) and dihydropyrimidine dehydrogenase (DPD) in advanced colorectal cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20051001

• An accurate dihydrouracil/uracil determination using improved high performance liquid chromatography method for preventing fluoropyrimidines-related toxicity in clinical practice.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20050905

• The role of thymidylate synthase and dihydropyrimidine dehydrogenase in resistance to 5-fluorouracil in human lung cancer cells.

  Lung cancer (Amsterdam, Netherlands) 20050901

• Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in a cohort of Caucasian individuals.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050815

• [Expression of dihydropyrimidine dehydrogenase in human colorectal carcinoma and its clinical implications].

  Zhonghua yi xue za zhi 20050810

• The activities of thymidine phosphorylase and dihydropyrimidine dehydrogenase in colorectal cancer depend on where the sample is taken.

  Oncology reports 20050801

• Prognostic predictors in breast cancer patients with postoperative 5-fluorouracil-based chemotherapy.

  International journal of molecular medicine 20050801

• BiDil raises questions about race as a marker.

  Nature reviews. Drug discovery 20050801

• Screening for dihydropyrimidine dehydrogenase deficiency.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050715

• Dihydropyrimidine dehydrogenase activity in 150 healthy Japanese volunteers and identification of novel mutations.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050715

• Correlations between antitumor activities of fluoropyrimidines and DPD activity in lung tumor xenografts.

  Oncology reports 20050701

• Thymidylate synthase predicts for clinical outcome in invasive breast cancer.

  Histology and histopathology 20050701

• Role of dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine against non-small cell lung cancer--in correlation with the tumoral expression of thymidylate synthase and dihydropyrimidine dehydrogenase.

  Lung cancer (Amsterdam, Netherlands) 20050701

• Pseudomembranous colitis associated with chemotherapy with 5-fluorouracil.

  Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20050701

• Prognostic significance of the thymidine phosphorylate/dihydropyrimidine dehydrogenase ratio in invasive cervical cancer.

  European journal of obstetrics, gynecology, and reproductive biology 20050701

• [Expression of metabolic enzymes of fluoropyrimidines in primary colorectal cancer and its clinical significance].

  Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences 20050618

• Action of human endonucleases III and VIII upon DNA-containing tandem dihydrouracil.

  DNA repair 20050608

• Thymidylate synthase and dihydropyrimidine dehydrogenase gene expression in breast cancer predicts 5-FU sensitivity by a histocultural drug sensitivity test.

  Cancer letters 20050601

• Improved analysis of 5-Fluorouracil and 5,6-dihydro-5-Fluorouracil by HPLC with diode array detection for determination of cellular dihydropyrimidine dehydrogenase activity and pharmacokinetic profiling.

  Therapeutic drug monitoring 20050601

• [Dihydropyrimidine deshydrogenase (DPD): rhythm and consequences].

  Pathologie-biologie 20050601

• Polymorphism of dihydropyrimidine dehydrogenase (DPYD) Cys29Arg and risk of six malignancies in Japanese.

  Nagoya journal of medical science 20050601

• Changes over time in thymidine phosphorylase and dihydropyrimidine dehydrogenase when colon cancer samples are left at room temperature.

  Cancer letters 20050510

• 5-Fluorouracil/irinotecan induced lethal toxicity as a result of a combined pharmacogenetic syndrome: report of a case.

  Journal of clinical pathology 20050501

• The unexpected structural role of glutamate synthase [4Fe-4S](+1,+2) clusters as demonstrated by site-directed mutagenesis of conserved C residues at the N-terminus of the enzyme beta subunit.

  Archives of biochemistry and biophysics 20050415

• Combined GADD45A and thymidine phosphorylase expression levels predict response and survival of neoadjuvant-treated gastric cancer patients.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050415

• Development of a stereological method to measure levels of fluoropyrimidine metabolizing enzymes in tumor sections using laser scanning cytometry.

  Cytometry. Part A : the journal of the International Society for Analytical Cytology 20050401

• [Relationship of serum level of dihydropyrimidine dehydrogenase and serum concentration of 5-fluorouracil to treatment response and adverse events in colorectal cancer patients].

  Ai zheng = Aizheng = Chinese journal of cancer 20050401

• Identification of three novel mutations in the dihydropyrimidine dehydrogenase gene associated with altered pre-mRNA splicing or protein function.

  Biological chemistry 20050401

• Crystallization and X-ray diffraction analysis of dihydropyrimidinase from Saccharomyces kluyveri.

  Acta crystallographica. Section F, Structural biology and crystallization communications 20050401

• Relationships among plasma [2-(13)C]uracil concentrations, breath (13)CO(2) expiration, and dihydropyrimidine dehydrogenase (DPD) activity in the liver in normal and dpd-deficient dogs.

  Drug metabolism and disposition: the biological fate of chemicals 20050301

• Phase II clinical trial of capecitabine in ovarian carcinoma recurrent 6-12 months after completion of primary chemotherapy, with exploratory TS, DPD, and TP correlates: a Gynecologic Oncology Group study.

  Gynecologic oncology 20050301

• Discovery of a novel N-iminylamidase activity: substrate specificity, chemicoselectivity and catalytic mechanism.

  Protein expression and purification 20050301

• Downregulation of TS, DPD, ERCC1, GST-Pi, EGFR, and HER2 gene expression after neoadjuvant three-modality treatment in patients with esophageal cancer.

  Journal of the American College of Surgeons 20050301

• Evaluation of TS-1 based treatment and expression of thymidylate synthase and dihydropyrimidine dehydrogenase on oral squamous cell carcinoma.

  Oral oncology 20050301

• A simple and sensitive fully validated HPLC-UV method for the determination of 5-fluorouracil and its metabolite 5,6-dihydrofluorouracil in plasma.

  Therapeutic drug monitoring 20050201

• Consensus interferon enhances the anti-proliferative effect of 5-fluorouracil on human hepatoma cells via downregulation of dihydropyrimidine dehydrogenase expression.

  Liver international : official journal of the International Association for the Study of the Liver 20050201

• Activator protein accelerates dihydropyrimidine dehydrogenase gene transcription in cancer cells.

  Cancer research 20050201

• Pharmacogenetic influences on treatment response and toxicity in colorectal cancer.

  Seminars in oncology 20050201

• Intratumoral molecular or genetic markers as predictors of clinical outcome with chemotherapy in colorectal cancer.

  Seminars in oncology 20050201

• [Assessment of dihydropyrimidine dehydrogenase and thymidylate synthase expression in gastric carcinoma and colonic carcinoma].

  Gan to kagaku ryoho. Cancer & chemotherapy 20050201

• Expression level of thymidylate synthase is a good predictor of chemosensitivity to 5-fluorouracil in colorectal cancer.

  Journal of gastroenterology 20050201

• Dihydropyrimidine dehydrogenase expression predicts survival outcome and chemosensitivity to 5-fluorouracil in patients with oral squamous cell carcinoma.

  Oral oncology 20050101

• Expression of dihydropyrimidine dehydrogenase, thymidylate synthase, p53 and p21 in metastatic liver tumor from colorectal cancer after 5-fluorouracil-based chemotherapy.

  Anticancer research 20050101

• Thymidylate synthase and dihydropyrimidine dehydrogenase in non-small cell lung cancer: relationship between mRNA expression and activity.

  Anticancer research 20050101

• Comparative analysis of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in colorectal cancer and surrounding normal tissue.

  Neoplasma 20050101

• Real-time RT-PCR (TaqMan) of tumor mRNA to predict sensitivity of specimens to 5-fluorouracil.

  Methods in molecular medicine 20050101

• Gender differences in the dihydropyrimidine dehydrogenase expression may contribute to higher toxicity in women treated with 5-fluorouracil therapy.

  Medical hypotheses 20050101

• Synthesis and anticonvulsant activity of some new hexahydropyrimidine-2,4-dione derivatives.

  Arzneimittel-Forschung 20050101

• Expression of thymidylate synthase, dihydropyrimidine dehydrogenase, thymidine phosphorylase, and orotate phosphoribosyl transferase in prostate cancer.

  Prostate cancer and prostatic diseases 20050101

• Sequence analysis of the 5'-flanking regions of human dihydropyrimidine dehydrogenase gene: identification of a new polymorphism related with effects of 5-fluorouracil.

  Nucleosides, nucleotides & nucleic acids 20050101

• Clinical application of immunoreactivity of dihydropyrimidine dehydrogenase (DPD) in gastric scirrhous carcinoma treated with S-1, a new DPD inhibitory fluoropyrimidine.

  Anticancer research 20050101

• Combination of oral fluoropyrimidine and docetaxel: reappraisal of synergistic effect against gastric carcinoma xenografts.

  In vivo (Athens, Greece) 20050101

• Circadian rhythm in dihydropyrimidine dehydrogenase activity and reduced glutathione content in peripheral blood of nasopharyngeal carcinoma patients.

  Chronobiology international 20050101

• Dihydropyrimidine dehydrogenase deficiency presenting at birth.

  Journal of inherited metabolic disease 20050101

• [Thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in soft-tissue sarcoma versus capecitabine potential].

  Voprosy onkologii 20050101

• Phylogenetic analysis and biochemical characterization of a thermostable dihydropyrimidinase from alkaliphilic Bacillus sp. TS-23.

  Antonie van Leeuwenhoek 20050101

• Expression levels of thymidine phosphorylase (TP) and dihydropyrimidine dehydrogenase (DPD) in patients with gastrointestinal cancer.

  Anticancer research 20050101

• Clinical role of thymidine phosphorylase and dihydropyrimidine dehydrogenase in colorectal cancer treated with postoperative fluoropyrimidine.

  Hepato-gastroenterology 20050101

• Complete cure of metastatic gastric cancer treated with combination chemotherapy using S-1.

  Hepato-gastroenterology 20050101

• Comprehensive analysis of pyrimidine metabolism in 450 children with unspecific neurological symptoms using high-pressure liquid chromatography-electrospray ionization tandem mass spectrometry.

  Journal of inherited metabolic disease 20050101

• Molecular characterization of established human colon carcinoma cell lines (HCT-8) made resistant to 5-fluorouracil by different selection schedules.

  Oncology research 20050101

• Mouse NEIL1 protein is specific for excision of 2,6-diamino-4-hydroxy-5-formamidopyrimidine and 4,6-diamino-5-formamidopyrimidine from oxidatively damaged DNA.

  Biochemistry 20041221

• Thymidylate synthase and dihydropyrimidine dehydrogenase gene expression in relation to differentiation of gastric cancer.

  International journal of cancer 20041220

• Tumor dihydropyrimidine dehydrogenase expression is a useful marker in adjuvant therapy with oral fluoropyrimidines after curative resection of colorectal cancer.

  Cancer chemotherapy and pharmacology 20041201

• Thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase expression, and histological tumour regression after 5-FU-based neo-adjuvant chemoradiotherapy in rectal cancer.

  The Journal of pathology 20041201

• Multiple organ failure due to 5-fluorouracil chemotherapy in a patient with a rare dihydropyrimidine dehydrogenase gene variant.

  Onkologie 20041201

• Should screening for DPD deficiency be mandatory before 5-FU exposure?

  Onkologie 20041201

• [Significance of tissue thymidine phosphorylase and dihydropyrimidine dehydrogenase activities in ovarian cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20041201

• Lethal toxicity after 5-fluorouracil chemotherapy and its possible relationship to dihydropyrimidine dehydrogenase deficiency: a case report and review of the literature.

  Journal of chemotherapy (Florence, Italy) 20041201

• Analysis of pyrimidine synthesis 'de novo' intermediates in urine and dried urine filter- paper strips with HPLC-electrospray tandem mass spectrometry.

  Clinical chemistry 20041101

• Clinical significance of dihydropyrimidine dehydrogenase in adjuvant 5-fluorouracil liver perfusion chemotherapy for pancreatic cancer.

  Annals of surgery 20041101

• Dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine S-1 may be effective against peritoneal dissemination in gastric cancer.

  Oncology reports 20041101

• Important role of the dihydrouracil/uracil ratio in marked interpatient variations of fluoropyrimidine pharmacokinetics and pharmacodynamics.

  Journal of clinical pharmacology 20041101

• Lack of contribution of dihydrofluorouracil and alpha-fluoro-beta-alanine to the cytotoxicity of 5'-deoxy-5-fluorouridine on human keratinocytes.

  Anti-cancer drugs 20041101

• [Relationship between dihydropyrimidine dehydrogenase(DPD) activity and toxicity of 5-FU-based adjuvant chemotherapy in colorectal cancer patients].

  Ai zheng = Aizheng = Chinese journal of cancer 20041101

• [Expressions of thymidine phosphorylase, thymidylate synthase and dihydropyrimidine dehydrogenase in breast cancer and their correlations with prognosis].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20041101

• Aberrant methylation of DPYD promoter, DPYD expression, and cellular sensitivity to 5-fluorouracil in cancer cells.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20041015

• Thymidylate synthase predictive power is overcome by irinotecan combination therapy with S-1 for gastric cancer.

  British journal of cancer 20041004

• Persistent twenty-four hour changes in liver and bone marrow despite suprachiasmatic nuclei ablation in mice.

  American journal of physiology. Regulatory, integrative and comparative physiology 20041001

• Improving patient care through molecular diagnostics.

  Seminars in oncology 20041001

• [Influence on 5-fluorouracil metabolism by combination of interferon-alpha and 5-fluorouracil against human hepatocellular carcinoma xenografts].

  Gan to kagaku ryoho. Cancer & chemotherapy 20041001

• Pyrimidine degradation defects and severe 5-fluorouracil toxicity.

  Nucleosides, nucleotides & nucleic acids 20041001

• Comparison of mRNA expression levels determined with TaqMan and competitive template RT-PCR.

  Nucleosides, nucleotides & nucleic acids 20041001

• [The thymidine phosphorylase to dihydropyrimidine dehydrogenase ratio in pancreatic cancer].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20041001

• Dihydopyrimidine dehydrogenase: a critical molecular biomarker for 5-Fluorouracil toxicity.

  Clinical colorectal cancer 20040901

• Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration.

  Clinical colorectal cancer 20040901

• [Prognosis and efficacy of postoperative adjuvant chemotherapy in colorectal cancer correlates with nucleic acid metabolizing enzymes].

  Gan to kagaku ryoho. Cancer & chemotherapy 20040901

• Dihydropyrimidine dehydrogenase: a flavoprotein with four iron-sulfur clusters.

  Biochimica et biophysica acta 20040901

• Peripheral neuropathy associated with capecitabine.

  Anti-cancer drugs 20040901

• Comparative pharmacology of oral fluoropyrimidines: a focus on pharmacokinetics, pharmacodynamics and pharmacomodulation.

  British journal of cancer 20040816

• Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA levels in tumor tissues and the efficacy of 5-fluorouracil in patients with non-small-cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20040801

• Thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in hepatocellular carcinoma and metastatic liver cancer.

  Oncology reports 20040801

• A simple and rapid high-performance liquid chromatographic (HPLC) method for 5-fluorouracil (5-FU) assay in plasma and possible detection of patients with impaired dihydropyrimidine dehydrogenase (DPD) activity.

  Journal of clinical pharmacy and therapeutics 20040801

• Dihydropyrimidine dehydrogenase deficiency: impact of pharmacogenetics on 5-fluorouracil therapy.

  Clinical advances in hematology & oncology : H&O 20040801

• The ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase in tumour tissues of patients with metastatic gastric cancer is predictive of the clinical response to 5'-deoxy-5-fluorouridine.

  European journal of cancer (Oxford, England : 1990) 20040701

• Bioactivation of capecitabine in human liver: involvement of the cytosolic enzyme on 5'-deoxy-5-fluorocytidine formation.

  Drug metabolism and disposition: the biological fate of chemicals 20040701

• [Choice of chemotherapeutic drugs for colorectal cancers by DPD and OPRT activities in cancer tissues].

  Gan to kagaku ryoho. Cancer & chemotherapy 20040701

• Doxifluridine-induced neurotoxicity with normal dihydropyrimidine dehydrogenase activity.

  Neurology 20040608

• Preoperative endoscopic analysis of thymidine phosphorylase and dihydropyrimidine dehydrogenase in gastrointestinal cancer.

  Oncology reports 20040601

• [Tumoral dihydropyrimidine dehydrogenase expression and efficacy of 5-fluorouracil plus leucovorin plus UFT therapy in patients with colorectal cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20040601

• [Thymidylate synthase and dihydropyrimidine dehydrogenase gene expressions in colorectal cancer using the Danenberg tumor profile method].

  Gan to kagaku ryoho. Cancer & chemotherapy 20040601

• Gene expression of 5-fluorouracil metabolic enzymes in primary colorectal cancer and corresponding liver metastasis.

  Cancer chemotherapy and pharmacology 20040501

• Establishment of enzyme-linked immunosorbent assays for thymidylate synthase and dihydropyriminide dehydrogenase in cancer tissues.

  Oncology reports 20040501

• Comparative analysis of thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in gastric and colorectal cancers.

  Oncology reports 20040501

• Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil.

  European journal of cancer (Oxford, England : 1990) 20040501

• Enzyme expression profiles suggest the novel tumor-activated fluoropyrimidine carbamate capecitabine (Xeloda) might be effective against papillary thyroid cancers of children and young adults.

  Cancer chemotherapy and pharmacology 20040501

• Dihydropyrimidine dehydrogenase pharmacogenetics in the Taiwanese population.

  Cancer chemotherapy and pharmacology 20040501

• Adjuvant chemotherapy for adenocarcinoma of the lung--is the standard of care ready for change?

  The New England journal of medicine 20040422

• Rapid identification of dihydropyrimidine dehydrogenase deficiency by using a novel 2-13C-uracil breath test.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20040415

• The efficacy of the combination therapy of 5-fluorouracil, cisplatin and leucovorin for hepatocellular carcinoma and its predictable factors.

  Cancer chemotherapy and pharmacology 20040401

• New insights in dihydropyrimidine dehydrogenase deficiency: a pivotal role for beta-aminoisobutyric acid?

  The Biochemical journal 20040401

• Expression of the oxidative base excision repair enzymes is not induced in TK6 human lymphoblastoid cells after low doses of ionizing radiation.

  Radiation research 20040401

• Single ascending dose tolerability, pharmacokinetic-pharmacodynamic study of dihydropyrimidine dehydrogenase inhibitor Ro 09-4889.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20040401

• [Estimation of level of enzyme induction of thymidine phosphorylase, dihydropyrimidine dehydrogenase, and thymidylate synthase in primary and recurrent breast cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20040401

• [Severe toxicity after treatment with capecitabine and fluorouracil due to partial dihydropyrimidine dehydrogenase deficiency].

  Nederlands tijdschrift voor geneeskunde 20040327

• Circadian expression of dihydropyrimidine dehydrogenase, thymidylate synthase, c-myc and p53 mRNA in mouse liver tissue.

  Ai zheng = Aizheng = Chinese journal of cancer 20040301

• [Assay method for uracil, dihydrouracil, 5-fluorouracil and 5-fluoro-5, 6-dihydrouracil by high-performance liquid chromatography].

  Gan to kagaku ryoho. Cancer & chemotherapy 20040301

• Tumor dihydropyrimidine dehydrogenase in stage II and III colorectal cancer: low level expression is a beneficial marker in oral-adjuvant chemotherapy, but is also a predictor for poor prognosis in patients treated with curative surgery alone.

  Cancer letters 20040210

• Substrate discrimination by formamidopyrimidine-DNA glycosylase: a mutational analysis.

  The Journal of biological chemistry 20040206

• Thymidine phosphorylase expression is preserved after radiotherapy in patients with cervical squamous cell carcinoma.

  Cancer chemotherapy and pharmacology 20040201

• Circadian rhythm of dihydrouracil/uracil ratios in biological fluids: a potential biomarker for dihydropyrimidine dehydrogenase levels.

  British journal of pharmacology 20040201

• [Clinical significance of TS and DPD activities in colorectal carcinoma as a predictive factor of UFT sensitivity].

  Gan to kagaku ryoho. Cancer & chemotherapy 20040201

• Dihydropyrimidine dehydrogenase and thymidylate synthase polymorphisms and their association with 5-fluorouracil/leucovorin chemotherapy in colorectal cancer.

  Clinical colorectal cancer 20040201

• Correlation of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase with sensitivity of gastrointestinal cancer cells to 5-fluorouracil and 5-fluoro-2'-deoxyuridine.

  World journal of gastroenterology 20040115

• Cancer pharmacogenetics.

  British journal of cancer 20040112

• Orchestration of base excision repair by controlling the rates of enzymatic activities.

  DNA repair 20040105

• Expression of thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase, E2F-1, Bak, Bcl-X, and Bcl-2, and clinical outcomes for gastric cancer patients treated with bolus 5-fluorouracil.

  Oncology reports 20040101

• DPD activity and immunohistochemical DPD expression in human breast cancer.

  Oncology reports 20040101

• The prognostic significance of thymidine phosphorylase, thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expressions in breast carcinomas.

  Histology and histopathology 20040101

• Quantification of 5,6-dihydrouracil by HPLC-electrospray tandem mass spectrometry.

  Clinical chemistry 20040101

• Differences in dihydropyrimidine dehydrogenase activities between gastric and colorectal cancer.

  Digestive diseases and sciences 20040101

• Immunohistochemical dihydropyrimidine dehydrogenase expression is a good prognostic indicator for patients with Dukes' C colorectal cancer.

  Anticancer research 20040101

• Mutations in exon 14 of dihydropyrimidine dehydrogenase and 5-Fluorouracil toxicity in Portuguese colorectal cancer patients.

  Genetics in medicine : official journal of the American College of Medical Genetics 20040101

• Dehydropyrimidine dehydrogenase deficiency in a cancer patient undergoing 5-fluorouracil chemotherapy.

  Anticancer research 20040101

• Changes in thymidylate synthase and its inhibition rate and changes in dihydropyrimidine dehydrogenase after the administration of 5-fluorouracil with cisplatin to nude mice with gastric cancer xenograft SC-1-NU.

  Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 20040101

• 5FU and oxaliplatin-containing chemotherapy in two dihydropyrimidine dehydrogenase-deficient patients.

  Anticancer research 20040101

• Head imaging abnormalities in dihydropyrimidine dehydrogenase deficiency.

  Journal of inherited metabolic disease 20040101

• Thymidylate synthetase (TS) genotype and TS/dihydropyrimidine dehydrogenase mRNA level as an indicator in determining chemosensitivity to 5-fluorouracil in advanced gastric carcinoma.

  Anticancer research 20040101

• Expression of dihydropyrimidine dehydrogenase in cancer cells but not in stromal cells predicts the efficacy of fluorouracil treatment in patients with gastric carcinoma.

  Anticancer research 20040101

• Drug interaction ontology (DIO) for inferences of possible drug-drug interactions.

  Studies in health technology and informatics 20040101

• Effects of TS-1 on peritoneal dissemination of gastric cancer in nude mice.

  Hepato-gastroenterology 20040101

• A comprehensive comparison of comparative RNA structure prediction approaches.

  BMC bioinformatics 20040101

• A phase II study of S-1 in patients with metastatic breast cancer--a Japanese trial by the S-1 Cooperative Study Group, Breast Cancer Working Group.

  Breast cancer (Tokyo, Japan) 20040101

• Evaluation of sensitivity to 5-FU on the basis of thymidylate synthase (TS)/dihydropyrimidine dehydrogenase (DPD) activity and chromosomal analysis in micro tissue specimens of breast cancer.

  Breast cancer (Tokyo, Japan) 20040101

• DNA lesion recognition by the bacterial repair enzyme MutM.

  The Journal of biological chemistry 20031219

• Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer.

  British journal of cancer 20031215

• Dihydropyrimidine dehydrogenase and thymidylate synthase activities in hepatocellular carcinomas and in diseased livers.

  Cancer chemotherapy and pharmacology 20031201

• Population study of expression of thymidylate synthase and dihydropyrimidine dehydrogenase in patients with solid tumors.

  International journal of molecular medicine 20031201

• Detailed analysis of five mutations in dihydropyrimidine dehydrogenase detected in cancer patients with 5-fluorouracil-related side effects.

  Human mutation 20031201

• [Support of TS-1, 5-FU preparation containing potent DPD inhibitor by determination of urinary uracil/serum 5-FU clearance].

  Gan to kagaku ryoho. Cancer & chemotherapy 20031201

• Evidence of alterations in base excision repair of oxidative DNA damage during spontaneous hepatocarcinogenesis in Long Evans Cinnamon rats.

  Cancer research 20031115

• Dihydropyrimidine dehydrogenase (DPD) rapidly regenerates after inactivation by eniluracil (GW776C85) in primary and metastatic colorectal cancer.

  Cancer chemotherapy and pharmacology 20031101

• Dihydropyrimidine dehydrogenase in normal and malignant endometrium: relationship with cell proliferation and thymidine phosphorylase.

  Virchows Archiv : an international journal of pathology 20031101

• Superior antitumour activity of S-1 in tumours with a high dihydropyrimidine dehydrogenase activity.

  European journal of cancer (Oxford, England : 1990) 20031101

• Both gene expression for orotate phosphoribosyltransferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine-based chemotherapy for metastatic colorectal cancer.

  British journal of cancer 20031020

• Use of pyrosequencing to detect clinically relevant polymorphisms in dihydropyrimidine dehydrogenase.

  Clinical chemistry 20031001

• Dihydropyrimidine dehydrogenase inhibition as a strategy for the oral administration of 5-fluorouracil: utility in the treatment of advanced colorectal cancer.

  Anti-cancer drugs 20031001

• [Results of prophylactic hepatic arterial chemotherapy for liver metastases of Dukes C colorectal cancer--correlation with tumoral expression of dihydropyrimidine dehydrogenase, thymidylate synthase, p53, or orotate phosphoribosyl transferase].

  Gan to kagaku ryoho. Cancer & chemotherapy 20031001

• Augmentation of the antitumor activity of capecitabine by a tumor selective dihydropyrimidine dehydrogenase inhibitor, RO0094889.

  International journal of cancer 20030920

• Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20030915

• Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil.

  British journal of cancer 20030901

• Effect of 5-fluorouracil and epidermal growth factor on cell growth and dihydropyrimidine dehydrogenase regulation in human uterine cervical carcinoma SKG-IIIb cells.

  Cancer science 20030901

• [PyNPase and DPD expression potentially predict response to 5'-DFUR treatment for node-positive breast cancer patients].

  Gan to kagaku ryoho. Cancer & chemotherapy 20030901

• [Immunohistologic evaluation of TS, DPD, and p53 protein expression in patients with colorectal cancer having liver and pulmonary metastases].

  Nihon rinsho. Japanese journal of clinical medicine 20030901

• [Molecular biological analysis of 5-fluorouracil sensitivity in colorectal neoplasm].

  Nihon rinsho. Japanese journal of clinical medicine 20030901

• [Response marker to 5-FU after curative surgery in colorectal cancer].

  Nihon rinsho. Japanese journal of clinical medicine 20030901

• [Tegafur--preoperative treatment with tegafur suppositories for rectal cancer].

  Nihon rinsho. Japanese journal of clinical medicine 20030901

• [Adjuvant chemotherapy for colorectal carcinoma after curative resection].

  Nihon rinsho. Japanese journal of clinical medicine 20030901

• [Significance of thymidylate synthase and dihydropyrimidine dehydrogenase activity in colon cancer].

  Nihon rinsho. Japanese journal of clinical medicine 20030901

• Quaternary structure of Azospirillum brasilense NADPH-dependent glutamate synthase in solution as revealed by synchrotron radiation x-ray scattering.

  The Journal of biological chemistry 20030808

• HU protein of Escherichia coli has a role in the repair of closely opposed lesions in DNA.

  The Journal of biological chemistry 20030801

• Impact of platinum complexes on dihydropyrimidine dehydrogenase activity in 5-fluorouracil-treated patients.

  Annals of oncology : official journal of the European Society for Medical Oncology 20030801

• Tailoring chemotherapy in advanced colorectal cancer.

  Current opinion in pharmacology 20030801

• Denaturing high performance liquid chromatography analysis of the DPYD gene in patients with lethal 5-fluorouracil toxicity.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20030801

• Quantitation of dihydropyrimidine dehydrogenase (DPD) mRNA expression levels in normal colon and colorectal cancer tumor paraffin-embedded tissue specimens.

  Anti-cancer drugs 20030801

• Pharmacogenomics in colorectal cancer.

  Seminars in oncology 20030801

• Rapid gas chromatographic-mass spectrometric diagnosis of dihydropyrimidine dehydrogenase deficiency and dihydropyrimidinase deficiency.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20030715

• Sensitive method for the quantification of urinary pyrimidine metabolites in healthy adults by gas chromatography-tandem mass spectrometry.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20030705

• Decline of nuclear and mitochondrial oxidative base excision repair activity in late passage human diploid fibroblasts.

  DNA repair 20030611

• 5-fluorouracil and dihydropyrimidine dehydrogenase.

  International journal of clinical oncology 20030601

• Clinical implications of dihydropyrimidine dehydrogenase (DPD) activity in 5-FU-based chemotherapy: mutations in the DPD gene, and DPD inhibitory fluoropyrimidines.

  International journal of clinical oncology 20030601

• [Circadian variations of dihydropyrimidine dehydrogenase (DPD) activity in oral mucosa of healthy volunteers].

  Pathologie-biologie 20030601

• Impact of dihydropyrimidine dehydrogenase on 5-fluorouracil treatment in cancer patients.

  European journal of medical research 20030530

• The novel DNA glycosylase, NEIL1, protects mammalian cells from radiation-mediated cell death.

  DNA repair 20030513

• 5-fluorouracil: mechanisms of action and clinical strategies.

  Nature reviews. Cancer 20030501

• Crystallization and preliminary X-ray diffraction analysis of thermophilic imidase from pig liver.

  Acta crystallographica. Section D, Biological crystallography 20030501

• A gene cluster involved in pyrimidine reductive catabolism from Brevibacillus agri NCHU1002.

  Biochemical and biophysical research communications 20030411

• The best of times...the worst of times.

  European journal of cancer (Oxford, England : 1990) 20030401

• Dihydropyrimidine dehydrogenase circadian rhythm in mouse liver: comparison between enzyme activity and gene expression.

  European journal of cancer (Oxford, England : 1990) 20030401

• Detection of a novel 1905C-->T mutation within the dihydropyrimidine dehydrogenase gene and potential for misclassification with the exon 14-skipping mutation.

  Clinical chemistry 20030401

• Diagnosis of dihydropyrimidine dehydrogenase deficiency in a neonate with thymine-uraciluria.

  Hong Kong medical journal = Xianggang yi xue za zhi 20030401

• Significance of thymidylate synthase activity in renal cell carcinoma.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20030401

• Relationships between the expression of thymidylate synthase, dihydropyrimidine dehydrogenase, and orotate phosphoribosyltransferase and cell proliferative activity and 5-fluorouracil sensitivity in colorectal carcinoma.

  International journal of clinical oncology 20030401

• [Thymidine phosphorylase is correlated with DPD in colon cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20030401

• Cancer pharmacogenomics: current and future applications.

  Biochimica et biophysica acta 20030317

• Design and synthesis of the tumor-activated prodrug of dihydropyrimidine dehydrogenase (DPD) inhibitor, RO0094889 for combination therapy with capecitabine.

  Bioorganic & medicinal chemistry letters 20030310

• Increased dihydropyrimidine dehydrogenase activity in breast cancer.

  Journal of surgical oncology 20030301

• Significance of dihydropyrimidine dehydrogenase activity in renal cell carcinoma.

  European journal of cancer (Oxford, England : 1990) 20030301

• High-throughput genotyping by DHPLC of the dihydropyrimidine dehydrogenase gene implicated in (fluoro)pyrimidine catabolism.

  International journal of oncology 20030201

• Regulation of dihydropyrimidine dehydrogenase gene expression in regenerating mouse liver.

  International journal of oncology 20030201

• Lethal 5-fluorouracil toxicity associated with a novel mutation in the dihydropyrimidine dehydrogenase gene.

  Annals of oncology : official journal of the European Society for Medical Oncology 20030201

• Combination of dihydropyrimidine dehydrogenase and thymidylate synthase gene expressions in primary tumors as predictive parameters for the efficacy of fluoropyrimidine-based chemotherapy for metastatic colorectal cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20030201

• Correlation between clinicopathologic factors and kinetics of metabolic enzymes for 5-fluorouracil given to patients with colon carcinoma by two different dosage regimens.

  Cancer chemotherapy and pharmacology 20030201

• Differential effects of two fluorouracil administration regimens for colorectal cancer.

  Oncology reports 20030101

• Clinical significance of thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in transitional cell cancer.

  Cancer chemotherapy and pharmacology 20030101

• Thymidine phosphorylase and dihydropyrimidine dehydrogenase in renal cell carcinoma: relationship between histological parameters and chemosensitivity to 5-fluorouracil.

  European urology 20030101

• Pharmacogenetic and clinical aspects of dihydropyrimidine dehydrogenase deficiency.

  Annals of clinical biochemistry 20030101

• [Combined determination of urine uracil levels and plasma 5-FU clearance for a simple order-made treatment with anticancer agents of FU derivative].

  Gan to kagaku ryoho. Cancer & chemotherapy 20030101

• Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA levels in thymoma.

  Surgery today 20030101

• Dihydropyrimidine dehydrogenase (DPD) activity in gastric cancer tissue and effect of DPD inhibitory fluoropyrimidines.

  Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 20030101

• Prediction of sensitivity to fluoropyrimidines by metabolic and target enzyme activities in gastric cancer.

  Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 20030101

• The stability of dihydropyrimidine dehydrogenase activity in colorectal cancer tissue after resection.

  Oncology reports 20030101

• Prognostic effects of dihydropyrimidine dehydrogenase in advanced colorectal cancer after surgery: immunohistochemistry using a new monoclonal antibody.

  Anticancer research 20030101

• The usefulness of immunohistochemical evaluation of dihydropyrimidine dehydrogenase for rectal cancer treated with preoperative radiotherapy.

  Hepato-gastroenterology 20030101

• Intratumoural thymidylate synthase and dihydropyrimidine dehydrogenase activities are good predictors of 5-fluorouracil sensitivity in colorectal cancer.

  The Journal of international medical research 20030101

• Mutational analysis of the human dihydropyrimidine dehydrogenase gene by denaturing high-performance liquid chromatography.

  Genetic testing 20030101

• Parenteral nutrition decreases hepatic dihydropyrimidine dehydrogenase activity and modulates catabolism of 5-fluorouracil in rats.

  In vivo (Athens, Greece) 20030101

• Quantitative analysis of thymidine phosphorylase and dihydropyrimidine dehydrogenase in renal cell carcinoma.

  Oncology 20030101

• Dihydropyrimidine dehydrogenase deficiency and acute neurological presentation.

  Journal of inherited metabolic disease 20030101

• High level concentration of pyrimidine nucleoside phosphorylase in esophageal squamous cell carcinoma but no correlation with clinicopathological parameters.

  Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus 20030101

• Forced expression of cytidine deaminase confers sensitivity to capecitabine.

  Oncology 20030101

• Effects of UFT on thymidylate synthase and dihydropyrimidine dehydrogenase activities in lung cancer.

  Anticancer research 20030101

• Up-regulation in dihydropyrimidine dehydrogenase activity by raltitrexed causes antagonism in combination with 5-fluorouracil.

  Anticancer research 20030101

• Repair of dihydrouracil supported by base excision repair in mNTH1 knock-out cell extracts.

  The Journal of biological chemistry 20021227

• Gender differences in the dihydropyrimidine dehydrogenase expression of colorectal cancers.

  Cancer letters 20021215

• Role of thymidine phosphorylase and dihydropyrimidine dehydrogenase in tumour progression and sensitivity to doxifluridine in gastric cancer patients.

  European journal of cancer (Oxford, England : 1990) 20021201

• Thymidylate synthase and dihydropyrimidine dehydrogenase expression in oral squamous cell carcinoma: an immunohistochemical and clinicopathologic study.

  Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics 20021201

• Predicting 5-FU sensitivity using human colorectal cancer specimens: comparison of tumor dihydropyrimidine dehydrogenase and orotate phosphoribosyl transferase activities with in vitro chemosensitivity to 5-FU.

  International journal of clinical oncology 20021201

• Dihydropyrimidine dehydrogenase levels in nonsmall-cell lung cancer tissues.

  International journal of clinical oncology 20021201

• Quantitative measurement of thymidylate synthase and dihydropyrimidine dehydrogenase mRNA level in gastric cancer by real-time RT-PCR.

  Japanese journal of cancer research : Gann 20021201

• [Mutations in the dihydropyrimidine dehydrogenase gene and their role in 5-fluororuracil intolerance].

  Zentralblatt fur Gynakologie 20021201

• Pyrazolylborate-zinc-nucleobase-complexes, 2:(1) preparations and structures of Tp(Cum,Me)Zn and Tp(Ph,Me)Zn complexes.

  Inorganic chemistry 20021118

• Biochemical modulation of 5-fluorouacil through dihydropyrimidine dehydrogenase inhibition: a Southwest Oncology Group phase II trial of eniluracil and 5-fluorouracil in advanced resistant colorectal cancer.

  Investigational new drugs 20021101

• [Hepatic recurrence after prophylactic hepatic arterial infusion of 5-fluorouracil for Dukes' C colorectal cancer--correlation with the expression of dihydropyrimidine dehydrogenase in the primary tumor].

  Gan to kagaku ryoho. Cancer & chemotherapy 20021101

• [Detection of DPD exon 14 skipping before fluorouracil treatment].

  Deutsche medizinische Wochenschrift (1946) 20021018

• Relationship between plasma concentrations of 5-fluorouracil and 5-fluoro-5,6-dihydrouracil and toxicity of 5-fluorouracil infusions in cancer patients.

  Therapeutic drug monitoring 20021001

• Predictive value of dihydropyrimidine dehydrogenase expression in tumor tissue, regarding the efficacy of postoperatively administered UFT (Tegafur + Uracil) in patients with p-stage I nonsmall-cell lung cancer.

  Journal of surgical oncology 20021001

• High prevalence of the IVS14 + 1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity.

  Pharmacogenetics 20021001

• Thymidine phosphorylase and dihydropyrimidine dehydrogenase activity in colorectal carcinoma and patients prognosis.

  Langenbeck's archives of surgery 20021001

• Induction of thymidine phosphorylase in both irradiated and shielded, contralateral human U87MG glioma xenografts: implications for a dual modality treatment using capecitabine and irradiation.

  Molecular cancer therapeutics 20021001

• Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14+1g>a mutation.

  International journal of cancer 20020920

• Screening and diagnosis of beta-ureidopropionase deficiency by gas chromatographic/mass spectrometric analysis of urine.

  Journal of mass spectrometry : JMS 20020901

• Identification and characterization of a novel human DNA glycosylase for repair of cytosine-derived lesions.

  The Journal of biological chemistry 20020823

• Development and characterization of a monoclonal antibody with cross-reactivity towards uracil and thymine, and its potential use in screening patients treated with 5-fluorouracil for possible risks.

  Clinica chimica acta; international journal of clinical chemistry 20020801

• [Molecular toxicological mechanism of the lethal interactions of the new antiviral drug, sorivudine, with 5-fluorouracil prodrugs and genetic deficiency of dihydropyrimidine dehydrogenase].

  Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 20020801

• [Significance of tissue PyNPase, TS, and DPD activities in breast cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20020801

• Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase.

  Biochimica et biophysica acta 20020718

• Simple liquid chromatographic method for the determination of uracil and dihydrouracil plasma levels: a potential pretreatment predictor of 5-fluorouracil toxicity.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20020715

• A high-throughput denaturing high-performance liquid chromatography method for the identification of variant alleles associated with dihydropyrimidine dehydrogenase deficiency.

  Analytical biochemistry 20020701

• Intratumoral dihydropyrimidine dehydrogenase messenger RNA level reflects tumor progression in human colorectal cancer.

  Annals of surgical oncology 20020701

• Bicyclic pyrimidine nucleoside analogues (BCNAs) as highly selective and potent inhibitors of varicella-zoster virus replication.

  The Journal of antimicrobial chemotherapy 20020701

• Modulation of intracellular glutathione concentration alters dehydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells.

  Clinical and experimental medicine 20020701

• Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics.

  Pharmacogenomics 20020701

• Enhancement of the antitumour activity of 5-fluorouracil (5-FU) by inhibiting dihydropyrimidine dehydrogenase activity (DPD) using 5-chloro-2,4-dihydroxypyridine (CDHP) in human tumour cells.

  European journal of cancer (Oxford, England : 1990) 20020601

• Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population.

  British journal of clinical pharmacology 20020601

• [Dihydropyrimidine dehydrogenase and thymidylate synthase in colon carcinoma].

  Gan to kagaku ryoho. Cancer & chemotherapy 20020601

• Thymidine kinase in epithelial ovarian cancer: relationship with the other pyrimidine pathway enzymes.

  International journal of cancer 20020520

• Novel disease-causing mutations in the dihydropyrimidine dehydrogenase gene interpreted by analysis of the three-dimensional protein structure.

  The Biochemical journal 20020515

• Lack of susceptibility of bicyclic nucleoside analogs, highly potent inhibitors of varicella-zoster virus, to the catabolic action of thymidine phosphorylase and dihydropyrimidine dehydrogenase.

  Molecular pharmacology 20020501

• Estimation of the effect of food on the disposition of oral 5-fluorouracil in combination with eniluracil.

  Cancer chemotherapy and pharmacology 20020501

• Impact of two weekly schedules of oral eniluracil given with fluorouracil and leucovorin on the duration of dihydropyrimidine dehydrogenase inhibition.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20020501

• Correspondence re: Raida, M. et al., prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20020501

• [The antitumor activity of DPD inhibitory-fluoropyrimidine (DIF) and non-DIF alone or in combination with paclitaxel against orthotopically implanted human breast cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20020501

• Porous graphitic carbon shows promise for the rapid screening partial DPD deficiency in lymphocyte dihydropyrimidine dehydrogenase in Chinese, Indian and Malay in Singapore by using semi-automated HPLC-radioassay.

  Clinical biochemistry 20020501

• Inhibiting 5-fluorouracil breakdown: a broken down approach to 5-fluorouracil modulation.

  Clinical colorectal cancer 20020501

• Can eniluracil improve 5-fluorouracil therapy?

  Clinical colorectal cancer 20020501

• How to calculate the dose of chemotherapy.

  British journal of cancer 20020422

• Crystal structure of the productive ternary complex of dihydropyrimidine dehydrogenase with NADPH and 5-iodouracil. Implications for mechanism of inhibition and electron transfer.

  The Journal of biological chemistry 20020412

• Reduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD gene.

  British journal of cancer 20020408

• Dihydropyrimidine dehydrogenase expression in preoperative biopsy and surgically resected specimens of gastric carcinoma.

  Cancer chemotherapy and pharmacology 20020401

• Dihydropyrimidine dehydrogenase-related enzymes predict efficacy and adverse reactions of UFT1+cisplatin neoadjuvant chemotherapy for gastric cancer.

  Anti-cancer drugs 20020401

• Measurement of endogenous uracil and dihydrouracil in plasma and urine of normal subjects by liquid chromatography-tandem mass spectrometry.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20020325

• Comparative pharmacokinetic study of continuous venous infusion fluorouracil and oral fluorouracil with eniluracil in patients with advanced solid tumors.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020315

• Mechanism(s) of antitumor action in protracted infusion of low dose 5-fluorouracil and cisplatin in gastric carcinoma.

  International journal of oncology 20020301

• [Detection of DPD-exon-14 skipping before 5-fluorouracil treatment?].

  Deutsche medizinische Wochenschrift (1946) 20020301

• A comparative analysis of translated dihydropyrimidine dehydrogenase cDNA; conservation of functional domains and relevance to genetic polymorphisms.

  Pharmacogenetics 20020301

• Profound dihydropyrimidine dehydrogenase deficiency resulting from a novel compound heterozygote genotype.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20020301

• [Correlation between clinical pathophysiologic factors and expression of orotate phosphoribosyl transferase (OPRT), thymidylate synthase (TS), and dihydropyrimidine dehydrogenase (DPD) in colorectal cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20020301

• A conserved family of Saccharomyces cerevisiae synthases effects dihydrouridine modification of tRNA.

  RNA (New York, N.Y.) 20020301

• Circadian variation of dihydropyrimidine dehydrogenase mRNA expression in leukocytes and serum cortisol levels in patients with advanced gastrointestinal carcinomas compared to healthy controls.

  Journal of cancer research and clinical oncology 20020201

• [Dihydropyrimidine dehydrogenase expression in gastric cancer using anti-human dihydropyrimidine dehydrogenase monoclonal antibody].

  Gan to kagaku ryoho. Cancer & chemotherapy 20020201

• Influence of liver dysfunction on dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells.

  Gan to kagaku ryoho. Cancer & chemotherapy 20020201

• Prognostic significance of dihydropyrimidine dehydrogenase expression in breast cancer.

  British journal of cancer 20020121

• Alternative nucleotide incision repair pathway for oxidative DNA damage.

  Nature 20020110

• Biopsy specimen microvessel density is a useful prognostic marker in patients with T(2-4)M(0) esophageal cancer treated with chemoradiotherapy.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20020101

• [A complete response after neoadjuvant chemotherapy for advanced gastric cancer with esophageal invasion].

  Gan to kagaku ryoho. Cancer & chemotherapy 20020101

• Thymidine phosphorylase and dihydropyrimidine dehydrogenase in bladder cancer.

  Urologia internationalis 20020101

• Prognostic significance of a combination of thymidylate synthase and dihydropyrimidine dehydrogenase activities in grades 1 and 2 superficial bladder cancer.

  Oncology reports 20020101

• Thymidine phosphorylase and dihydropyrimidine dehydrogenase levels in primary colorectal cancer show a relationship to clinical effects of 5'-deoxy-5-fluorouridine as adjuvant chemotherapy.

  Oncology reports 20020101

• Clinical pharmacokinetics of 5-fluorouracil with consideration of chronopharmacokinetics.

  Chronobiology international 20020101

• Roles of thymidylate synthase and dihydropyrimidine dehydrogenase in tumor progression and sensitivity to 5-fluorouracil in human gastric cancer.

  Anticancer research 20020101

• Association of time to recurrence with thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression in stage II and III colorectal cancer.

  Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 20020101

• Dihydropyrimidine dehydrogenase enzyme deficiency: clinical and genetic assessment of prevalence in Turkish cancer patients.

  Cancer investigation 20020101

• The effect of dihydropyrimidine dehydrogenase deficiency on outcomes with fluorouracil.

  Adverse drug reactions and toxicological reviews 20020101

• Tumor dihydropyrimidine dehydrogenase activity in advanced cervical carcinoma.

  Oncology reports 20020101

• Role of dihydropyrimidine dehydrogenase activity in patients with esophageal cancer.

  Anticancer research 20020101

• DNA polymerase beta is the major dRP lyase involved in repair of oxidative base lesions in DNA by mammalian cell extracts.

  The EMBO journal 20011203

• Thymidylate synthase and dihydropyrimidine dehydrogenase activities in non-small cell lung cancer tissues: relationship with in vitro sensitivity to 5-fluorouracil.

  Lung cancer (Amsterdam, Netherlands) 20011201

• Retroviral transduction of human dihydropyrimidine dehydrogenase cDNA confers resistance to 5-fluorouracil in murine hematopoietic progenitor cells and human CD34+-enriched peripheral blood progenitor cells.

  Cancer gene therapy 20011201

• [Activities of thymidylate synthase and dihydropyrimidine dehydrogenase in patients with colorectal cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20011201

• Detection of beta-ureidopropionase deficiency with HPLC-electrospray tandem mass spectrometry and confirmation of the defect at the enzyme level.

  Journal of inherited metabolic disease 20011201

• Unique misinsertion specificity of poliota may decrease the mutagenic potential of deaminated cytosines.

  The EMBO journal 20011115

• Fluorouracil (5FU) pharmacokinetics in 5FU prodrug formulations with a dihydropyrimidine dehydrogenase inhibitor.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20011115

• Dihydropyrimidine dehydrogenase mRNA level correlates with the response to 5-fluorouracil-based chemo-immuno-radiation therapy in human oral squamous cell cancer.

  International journal of oncology 20011101

• [Dihydropyrimidine dehydrogenase activity in urothelial cancer--influence of UFT administration on DPD activity].

  Gan to kagaku ryoho. Cancer & chemotherapy 20011101

• Synthesis and evaluation of N-acyl-2-(5-fluorouracil-1-yl)-D,L-glycine as a colon-specific prodrug of 5-fluorouracil.

  Journal of pharmaceutical sciences 20011101

• High-performance liquid chromatographic assay with ultraviolet detection for quantification of dihydrofluorouracil in human lymphocytes: application to measurement of dihydropyrimidine dehydrogenase activity.

  Journal of chromatography. B, Biomedical sciences and applications 20011025

• Thymidine phosphorylase and dihydropyrimidine dehydrogenase protein expression in colorectal cancer.

  International journal of cancer 20011015

• High expression of thymidylate synthase leads to resistance to 5-fluorouracil in biliary tract carcinoma in vitro.

  Japanese journal of cancer research : Gann 20011001

• [Evaluation of chemosensitivity testing by CD-DST, and TS and DPD activity in cases of colorectal liver].

  Gan to kagaku ryoho. Cancer & chemotherapy 20011001

• [Immunohistochemical study of dihydropyrimidine dehydrogenase (DPD) and p53 in biopsied specimens of esophageal cancer before chemoradiotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20011001

• [Effect of peroral doxifluridine plus hepatic arterial infusion for synchronous liver metastasis of colorectal cancer--correlation with the expression of thymidine phosphorylase and dihydropyrimidine dehydrogenase in primary colorectal cancer lesions].

  Gan to kagaku ryoho. Cancer & chemotherapy 20011001

• Variations in 5-fluorouracil concentrations of colorectal tissues as compared with dihydropyrimidine dehydrogenase (DPD) enzyme activities and DPD messenger RNA levels.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20010901

• Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20010901

• Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients.

  Annals of oncology : official journal of the European Society for Medical Oncology 20010901

• Changes in intratumoral thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD) mRNA expression in colorectal and gastric cancer during continuous tegafur infusion.

  International journal of oncology 20010801

• Simple gas chromatographic-mass spectrometric procedure for diagnosing pyrimidine degradation defects for prevention of severe anticancer side effects.

  Journal of chromatography. B, Biomedical sciences and applications 20010705

• Extraction of 5-fluorouracil by tumor and liver: a noninvasive positron emission tomography study of patients with gastrointestinal cancer.

  Cancer research 20010701

• Eukaryotic beta-alanine synthases are functionally related but have a high degree of structural diversity.

  Genetics 20010701

• Peripheral neuropathy associated with weekly oral 5-fluorouracil, leucovorin and eniluracil.

  Anti-cancer drugs 20010701

• [Tumoral levels of thymidine phosphorylase and dihydropyrimidine dehydrogenase in elderly colorectal cancer patients].

  Gan to kagaku ryoho. Cancer & chemotherapy 20010601

• Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20010501

• CPT-11 alters the circadian rhythm of dihydropyrimidine dehydrogenase mRNA in mouse liver.

  Japanese journal of cancer research : Gann 20010501

• [Significance of pyrimidine nucleoside phosphorylase (PyNPase) and dihydropyrimidine dehydrogenase (DPD) in advanced gastric cancers].

  Gan to kagaku ryoho. Cancer & chemotherapy 20010501

• [Correlation between 5-fluorouracil (5-FU) sensitivity as measured by collagen gel droplet embedded culture drug sensitivity test (CD-DST) and expression of orotate phosphoribosyl transferase (OPRT), thymidylate synthase (TS), and dihydropyrimidine dehydrogenase (DPD) in colorectal cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20010501

• A possible role of Ku in mediating sequential repair of closely opposed lesions.

  The Journal of biological chemistry 20010420

• Discrepancies between the gene expression, protein expression, and enzymatic activity of thymidylate synthase and dihydropyrimidine dehydrogenase in human gastrointestinal cancers and adjacent normal mucosa.

  International journal of oncology 20010401

• Phase II study of oral eniluracil, 5-fluorouracil, and leucovorin in patients with advanced colorectal carcinoma.

  Cancer 20010401

• Thymidine kinase, thymidylate synthase, and dihydropyrimidine dehydrogenase profiles of cell lines of the National Cancer Institute's Anticancer Drug Screen.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20010401

• [5-fluorouracil and dihydropyrimidine dehydrogenase].

  Gan to kagaku ryoho. Cancer & chemotherapy 20010401

• Safe administration of irinotecan, oxaliplatin and raltitrexed in a DPD-deficient patient with metastatic colon cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20010401

• [TS-1 therapy for advanced gastric cancer].

  Nihon rinsho. Japanese journal of clinical medicine 20010401

• [Capecitabine (Ro09-1978) for therapy of advanced and recurrent gastric cancer].

  Nihon rinsho. Japanese journal of clinical medicine 20010401

• Inhibition of oxidative DNA repair in cadmium-adapted alveolar epithelial cells and the potential involvement of metallothionein.

  Toxicology 20010321

• Determinants of prognosis and response to therapy in colorectal cancer.

  Current oncology reports 20010301

• Synergistic efficacy of 3n-butyrate and 5-fluorouracil in human colorectal cancer xenografts via modulation of DNA synthesis.

  Gastroenterology 20010301

• Germline mutation of dihydropyrimidine dehydrogenese gene among a Japanese population in relation to toxicity to 5-Fluorouracil.

  Japanese journal of cancer research : Gann 20010301

• The significance of dihydropyrimidine dehydrogenase (DPD) activity in bladder cancer.

  European journal of cancer (Oxford, England : 1990) 20010301

• Rapid detection of a common dihydropyrimidine dehydrogenase mutation associated with 5-fluorouracil toxicity and congenital thymine uraciluria using fluorogenic hybridization probes.

  Clinical biochemistry 20010301

• Effects of PR-350, a newly developed radiosensitizer, on dihydropyrimidine dehydrogenase activity and 5-fluorouracil pharmacokinetics.

  Cancer chemotherapy and pharmacology 20010301

• UFT plus oral leucovorin calcium (Orzel) and radiation in combined modality therapy: a comprehensive review.

  International journal of cancer 20010220

• Crystal structure of dihydropyrimidine dehydrogenase, a major determinant of the pharmacokinetics of the anti-cancer drug 5-fluorouracil.

  The EMBO journal 20010215

• Clinical relevance of the concentrations of both pyrimidine nucleoside phosphorylase (PyNPase) and dihydropyrimidine dehydrogenase (DPD) in colorectal cancer.

  Japanese journal of clinical oncology 20010201

• 5-FU multifocal inflammatory leukoencephalopathy and dihydropyrimidine dehydrogenase deficiency.

  Neurology 20010109

• Crystallization and preliminary X-ray study of pig liver dihydropyrimidine dehydrogenase.

  Acta crystallographica. Section D, Biological crystallography 20010101

• Clinical implications of dihydropyrimidine dehydrogenase on 5-FU pharmacology.

  Oncology (Williston Park, N.Y.) 20010101

• Oral eniluracil/5-FU for advanced colon and breast carcinomas.

  Oncology (Williston Park, N.Y.) 20010101

• The oral fluorinated pyrimidines.

  Investigational new drugs 20010101

• Dihydropyrimidine dehydrogenase activity of cancerous and non-cancerous tissues in liver and large intestine.

  Oncology reports 20010101

• Lack of interaction between bropirimine and 5-fluorouracil on human dihydropyrimidine dehydrogenase.

  Xenobiotica; the fate of foreign compounds in biological systems 20010101

• Importance of dihydropyrimidine dehydrogenase (DPD) deficiency in patients exhibiting toxicity following treatment with 5-fluorouracil.

  Advances in enzyme regulation 20010101

• [Dihydropyrimidine dehydrogenase deficiency].

  Ryoikibetsu shokogun shirizu 20010101

• Dihydropyrimidine dehydrogenase activity and thymidylate synthase level are associated with response to 5-fluorouracil in human colorectal cancer.

  The Kurume medical journal 20010101

• Therapy of disseminated colorectal cancer: the emerging role of intratumoral molecular biology.

  The European journal of surgery. Supplement. : = Acta chirurgica. Supplement 20010101

• Structure-activity relationship of ligands of uracil phosphoribosyltransferase from Toxoplasma gondii.

  Biochemical pharmacology 19940817

• Beta-alanine synthesis in Escherichia coli.

  Journal of bacteriology 19800301